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We don’t know whether there is light at the end of the tunnel, but we are 
pretty convinced that there is a tunnel. 
-Unknown 
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Abstract 
Prostate cancer is the most frequently diagnosed malignant disorder in men 
and despite intensive research there is little effective therapy against tumour 
recurrence and metastatic disease. Recent findings direct the origins of 
prostate cancer to cancer stem cells (CSCs). The CSC model proposes that 
tumours are hierarchically organized and sustained by CSCs that act as an 
undifferentiated reservoir within the tumour. Similar to their normal 
counterparts, CSCs are thought to be highly protected against DNA damage, 
which might play a crucial role in therapy failure and tumour recurrence. 
Our findings indicate that CD133+/α2β1integrinhigh stem cells (SCs) from 
malignant and benign prostate tissues are more effectively protected against 
DNA damage introduced by etoposide than CD133-/α2β1integrinhigh transit 
amplifying (TAs) and CD133-/α2β1integrinlow committed basal cells (CBs). 
Furthermore, the colony forming efficiency in prostate SCs was less affected 
by the drug. The assessment of ABC-transporters revealed that these are 
unlikely to be mediators of the enhanced resistance in SCs. However, 
according to a cell cycle analysis a higher proportion of SCs was quiescent 
when compared to TA or CB populations. Hence, cellular dormancy might be 
one factor contributing to therapy survival. Further research is required to 
determine the role of CSCs in treatment resistance. Future therapies that 
target specifically prostate CSCs might be a key to prevent tumour relapse. 
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1. INTRODUCTION 
1.1 The prostate  
The prostate is a walnut-sized gland of the mammalian reproductive system 
that produces ~30% of the seminal fluid [1]. The function of this secretion is 
to provide nutrients and anticoagulants for the spermatozoa, which are 
mixed in the urethra. According to McNeal’s classification, the prostate 
consists of four zones (Figure 1-1) [2]. The peripheral zone constitutes 
more than 70% of the prostate and surrounds the urethra [2, 3]. The 
majority of prostate carcinomas arise from here [2]. The second largest zone 
is the central zone, which surrounds the ejaculatory ducts [2, 3]. The 
transitional zone makes up 5% of the prostate [2, 3]. It is the zone where 
benign prostatic hyperplasia (BPH) and approximately 25% of prostate 
carcinomas occur [2, 3]. The anterior zone contains mainly fibrous and 
muscular tissue and has no secretory function [2]. The normal prostate 
epithelium consists of three major cell types: luminal cells, basal cells and 
neuroendocrine cells (NEs) (Figure 1-2) [3, 4]. The predominant cell type are 
the luminal cells [4]. They are terminally differentiated and produce prostate 
specific antigen (PSA), a serine-protease that prevents the coagulation of 
seminal fluid. Furthermore, they secrete prostatic acid phosphatase (PAP) 
and beta microseminoprotein [3, 5]. As their growth and survival depends on 
androgens e.g. testosterone, they express the androgen receptor (AR) [6, 7].  
The population of luminal cells has a high apoptotic rate and hence a short 
life time leading to a fast turn-over [3, 8]. 
The basal cells of the prostate epithelium are less differentiated and do not 
have secretory activity [4]. They are androgen-independent and express 
only low levels of AR [9, 10]. The basal epithelium is the most proliferative 
compartment and is made up in a hierarchical order (Figure 1-2) [4]. There 
                                                                                             INTRODUCTION 
21 
 
is a rare subset of stem cells (SCs) that ensures the regeneration of the 
prostate tissue [11, 12]. They are located within a supporting environment, 
the so-called “stem cell niche”, which provides signals that are essential for 
their survival. Furthermore, in the niche the SCs are protected from signals 
that would result in their differentiation and apoptosis, that would otherwise 
result in an exhaustion of the SC pool [3, 13, 14].  
To fuel the tissue with new cells, SCs give rise to basal, luminal and NEs, a 
process which is mediated by alternative differentiation pathways [3, 15]. 
During differentiation, the cells migrate through the basal layer to form 
terminally differentiated cells [3, 16]. The SCs give rise to transit amplifying 
cells (TAs) and these proceed to differentiate upon stimulation with 
androgens, stromal factors and signals from the extracellular matrix into 
committed basal cells (CBs), which develop into fully differentiated luminal 
cells [17-19]. The prostate epithelium is illustrated in Figure 1-2. 
The NEs reside in the epithelium of the acini and ducts. They are terminally 
differentiated and androgen-independent [20]. NEs secrete a variety of 
hormones, such as serotonin, bombensin, neurotensin and calcitonin, which 
regulate the growth of the prostate [3, 21]. Underneath the epithelium there 
is the stromal compartment, which comprises different structures such as 
smooth muscle cells, fibroblasts, adipocytes, collagen and elastin [3]. The 
stromal compartment is critical for the maintenance of the prostate gland by 
the secretion of growth factors [22]. 
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Figure 1-1 Zones of the prostate. Illustration of the prostate showing the central, 
anterior (fibromuscular), transitional and peripheral zone. Taken from [23].   [3].  
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Figure 1-2 Anatomy of the prostate gland. The prostate gland consists of many 
fluid-filled ducts. The cellular structure within the ducts consists of an epithelium of 
undifferentiated basal cells (SCs, TAs, CBs; CD44/CK5/CK14+) and differentiated 
luminal cells (CD24/CK18/PSA/PAP/AR+) that have a secretory function. The 
neuroendocrine (ChrA+) cells are protruding through both layers. The basal layer 
also contains a small population of SCs (CD133+/α2β1high) that give rise to the 
differentiated cells within the epithelium. The prostate epithelium is separated from 
the stromal compartment by the basement membrane. The stromal fraction consists 
of fibroblasts and collagen. Modified and reproduced from [3, 4]. 
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1.1.1 Non-malignant diseases of the prostate 
1.1.1.2 BPH 
 BPH is a benign outgrowth of cells in the prostate that frequently occurs in 
ageing men. The disease is a result of a deregulated proliferation of the 
epithelial and stromal compartments [24, 25]. BPH is often treated with 
trans-urethral resections of the prostate (TURP) surgery to reduce a high 
frequency of urination owing to increased pressure on the bladder [3]. BPH 
is not thought to be involved in malignant transformation as it is localized in 
the transition zone of the prostate, whereas prostate cancer usually occurs 
in the peripheral zone [26]. 
1.1.1.3 Prostate intraepithelial neoplasia (PIN) 
PIN is caused by an increased cell proliferation that causes, similar to 
prostate cancer, a degeneration of the basal-luminal cell stratification, even 
if the integrity of the basement membrane is maintained [3, 27]. High grade 
PIN (HGPIN) has been described as a pre-cancerous condition with 
progression to cancer after 5 years or more [3, 28-30]. 
1.2 Prostate cancer 
1.2.1 Incidence and risk factors of prostate cancer 
Cancer is one of the most common diseases leading to death in western 
countries. One of the most frequently diagnosed malignant disorders in men 
in the UK is the development of tumours in the prostate (Figure 1-3). 
According to Jemal et al. prostate cancer is the second leading cause of male 
cancer-related death in the USA and UK (12% of all male cancer related 
deaths) [31, 32]. Despite its strong geographical dependence, other risk 
factors include age, ethnic origin and diet [33]. Whereas prostate cancer is 
uncommon in young men, almost one-third of men around 50 years of age 
already have histologically identifiable prostate tumours and incidence rises 
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for men in their 80s [33-35]. Concerning the ethnic origin, the highest 
incidence is found in African Americans [33, 36]. Also diet has been 
extensively researched due to the variation in prostate cancer incidence 
between different countries. Calcium from dietary or supplemental sources 
has been associated with an increased prostate cancer risk, whereas 
lycopene and selenium were linked with a decreased risk in some studies 
[37]. 
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Figure 1-3 The 10 most commonly diagnosed cancers in men (excluding non-
melanoma skin cancer) in the UK. Reproduced  from CRUK statistics, 2009.  
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                             INTRODUCTION 
27 
 
1.2.2 Diagnosis of prostate cancer 
The diagnosis of prostate cancer relies on the determination of serum levels 
of the protein PSA that is secreted by prostate luminal cells. Elevated levels 
of PSA are linked to malignancy [3, 38]. However, in some cases the PSA test 
fails. Even though the PSA test is a commonly used method, it cannot 
distinguish aggressive from non-aggressive cancers [33]. As a consequence, 
false positive results can result in patients undergoing unnecessary surgery 
[33].  There is a 5% rate of false-positive and 2% rate of false negative 
results [3, 39]. PSA is not exclusively secreted by the prostate and can also 
be expressed by other tissues such as the lung [33, 40]. Furthermore, high 
PSA levels are not necessarily linked to malignancy and may be a result of 
PIN, inflammation or infection [3, 41, 42]. In regard to false-negative results, 
a study revealed that even some individuals with normal PSA levels had 
prostate tumours [43].  
However, the next step after the detection of high PSA levels (>4 ng/ml) is 
the preparation of a biopsy for histological analysis to confirm the presence 
of the tumour and its grade of malignancy [3]. The tissue is examined 
according to the Gleason grading system, which was established in the 
sixties and remains the most important clinical prognostic factor (Figure 1-
4), [33, 44]. Two areas of the tissue with the most common and second most 
common tumour pattern are scored with the values 1-5. A normal cellular 
structure would be assigned with 1, whereas the value 5 would represent a 
highly malignant condition featured by loss of the common basal-luminal 
bilayer and integrity of the basement membrane. To determine the Gleason 
score both values are added. Hence, the lowest Gleason score can be 2 and 
the highest 10. Gleason scores over 7 are usually correlated with a poor 
clinical outcome [3, 45]. Other diagnostic methods which are particularly 
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used to assess the tumour progression are magnetic resonance imaging 
(MRI) or computer tomography (CT) scan [33]. 
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Figure 1-4 The Gleason grading system. Biopsies taken from prostate tissue are 
analyzed on the basis of their cellular morphology in order to identify disease 
related alterations. Pattern 1 represents healthy tissue consisting of small uniform 
glands. At pattern 2 there is more stroma between the tissue. Both, pattern 1 and 
pattern 2 are well differentiated. At pattern 3 there is a distinct infiltration from the 
cells at the margins of the gland and the cells are only moderately differentiated. At 
pattern 4 neoplastic cells arise and there are only very few glands. Pattern 5 is 
characterized by a lack of glands. Pattern 4 and 5 are poorly differentiated. Taken 
from [46].  
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1.2.3 Treatment of prostate cancer 
The treatment modality depends on the progression/stage of the disease, 
which is for prostate cancer, assessed by the previously described 
diagnostic methods. Therapies for localized prostate cancer (tumours are 
contained within the prostate capsule) include watchful waiting, radical 
prostatectomy (surgical removal of the prostate) or radiotherapy which can 
be applied in form of external-beam radiation or brachytherapy 
(implantation of radioactive seeds into the prostate) [33, 47-49]. When 
metastases are found, these treatment options have only a limited efficacy 
with the result of a relapse of the disease. 
A frequent therapy for advanced prostate cancer is androgen deprivation 
therapy (ADT). Owing to their importance in PSA production, cell survival, 
growth and proliferation, AR signalling pathways are a critical target for 
prostate cancer treatment [50, 51]. ADT can be conducted by chemical 
castration through substances designed to block AR signalling e.g. by 
gonodotropin-releasing hormone analogs or direct inhibition of the 
androgen receptor activity [33]. Furthermore it can also be achieved by 
surgical castration [33].  
However,  with ADT the patients´ life can be prolonged for rarely more than 
2 years as tumours become castration resistant (CRPC) [33, 52].  Upon 
failure of ADT, the application of chemotherapeutic drugs, such as 
docetaxel or novel androgen ablation therapies, are used as a last line of 
treatment. These treatments typically only extend the patients´ life for up to 
2 years and help to reduce the symptoms [53, 54].  
Mitoxantrone was the first chemotherapeutic drug approved for the 
treatment of CRPC. Today it is typically given as a second-line treatment, 
where it can have palliative improvement for patients with cancer 
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progression after treatment with docetaxel [33]. New drugs such as 
abiraterone are used to decrease the testosterone levels, but they can only 
extend the mean life time expectancy of a patient with CRPC by a few 
months with little prospect of curing the disease [33, 55].  
Research into new treatments against prostate cancer is crucial, as CRPC 
and also radiorecurrent prostate cancer present a serious issue with 30% of 
patients relapse [56-59]. There are a few new treatment strategies with 
success in clinical trials, including photodynamic therapy (PDT), high 
intensity focused ultrasound (HIFU), cryotherapy, gene therapy and 
immunotherapy, including vaccines [60-62]. HIFU, cryotherapy and PDT are 
focal therapies and target specific cancer areas, with minimum damage to 
normal tissue and reduced side effects [33, 63]. 
In conclusion, despite intensive research there are currently no therapies 
available that eliminate treatment-resistant secondary tumours and 
metastatic disease. Further research is required to find novel therapeutic 
targets and treatment strategies. Recent findings direct the origins of 
prostate cancer to cancer stem cells (CSCs) that might be a new therapeutic 
target.  
1.2.4 Development of prostate cancer 
1.2.4.1 The stages of prostate cancer 
Prostate cancer development is defined by four basic stages. At stage 1 the 
tumour is small and localized inside the prostate gland [64]. At stage 2 the 
cancer is still located in the prostate gland, but is enlarged in comparison to 
stage 1 [64]. A hard lump might be felt during rectal examination [64]. At 
stage 3 the cancer has broken through the outer layer of the prostate gland 
to tissues such as the seminal vesicles [64]. In the most advanced condition, 
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stage 4, the cancer spreads to more distant locations such as the lymph 
nodes, bones, bladder, rectum, liver or lungs [64]. 
In advanced stages of prostate cancer, primary tumour cells acquire the 
ability to escape from the prostate capsule by expression of enzymes that 
inactivate substrate-anchoring proteins [3]. One example is the 
upregulation of heparanase that cleaves heparin-sulphate-modified 
proteoglycans in the extracellular matrix (ECM) [3, 65]. The malignant cells 
migrate to secondary locations through lymph node drainage or the vascular 
system [3]. There is also increasing evidence that aberrant stromal 
components play a role in tumour progression [3, 66].  
1.2.4.2 Genetic changes in prostate cancer  
Although no single tumour suppressor gene responsible for the onset of the 
disease has been identified yet, there are a number of candidate genes [67]. 
However, the loss of particular genes allows the progression of the disease 
at each stage (Figure 1-5) [67]: The loss of NKX3.1 is linked to the 
transformation of the normal prostate epithelium to PIN. PTEN and Rb loss 
allow the progression from PIN to the development of invasive carcinoma 
and loss of p53 function is often found at metastatic stages of the disease 
[67]. Also the AR gene plays a role in the malignant prostate and has been 
shown to have numerous sequence alterations in prostate cancer [68]. The 
AR binds to testosterone and is responsible for the transcription of genes 
that stimulate the growth of the normal prostate gland, but also of prostate 
cancer cells [68]. Furthermore, aberrant AR signalling is a main obstacle in 
androgen ablation therapy [68]. 
Genetic changes in the prostate can also occur at a gross level e.g. through 
chromosomal aberrations such as the TMPRSS2:ERG fusion, which was found 
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in 20% of HGPIN and 50-70% of patients with prostate cancer [3, 69, 70]. 
Also epigenetic mechanisms have been linked to prostate cancer [3]. For 
example a commonly inactivated gene through promoter hypermethylation 
is glutathiontransferase 1 (GSTP1) [71]. In prostate cancer GSTP1 expression 
is lost in almost 90% of tumours and 70% of PIN, making it to an early event 
in prostate carcinogenesis [71]. Another example is the inactivation of 
TIMP-2 through promoter hypermethylation [3, 72]. A normally functional 
TIMP-2 gene would prevent tumour invasion and metastasis [3, 73].  
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Figure 1-5 The progression of prostate cancer. Schematic presentation of the 
transformation of the normal prostate epithelium to prostate cancer and the loss of 
genes associated with each stage. Reproduced from [3, 67]. 
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1.3 CSCs 
Recent findings direct the origins of many cancers to CSCs rather than 
deregulated differentiated cells. Also prostate cancer was originally treated 
as a disease that developed from terminally differentiated luminal cells. 
When reconsidering the origin of prostate cancer it may be more logical to 
attribute the onset of the disease to oncogenic changes in basal cells and 
SCs [4]. The reason being, SCs persist during the life time of the host and 
the risk for the accumulation of mutations is therefore much higher than in 
progenitors or differentiated cells [4]. Also crucial pathways required for SC 
maintenance are correlated with carcinogenesis [74]. 
1.3.1 Normal SCs  
SCs have the unique capacity for differentiation and self-renewal which 
distinguishes them from any other cell type. The self-renewal capacity 
ensures the maintenance of SCs during the life time of the host. It comprises 
asymmetric and symmetric cell division. Asymmetric cell division produces 
an identical daughter SC and a progenitor cell that can differentiate into a 
specific cell type of the tissue (Figure 1-6) [75]. A symmetric cell division 
generates two identical daughter SCs. Hence, asymmetric cell divisions 
maintain a constant number of SCs, whereas symmetric cell divisions 
increase the SC number. SCs can be mainly divided into embryonic SCs and 
adult SCs. Embryonic SCs are found in the inner cell mass of the blastocyst. 
They are defined as a population of undifferentiated pluripotent cells. Owing 
to their pluripotent character they are able to give rise to the three germ 
layers (mesoderm, ectoderm, endoderm) that later on develop into the 
specific tissues of the organism. Adult SCs or tissue specific SCs are derived 
from embryonic SCs. As embryonic SCs they form a reservoir of 
undifferentiated cells, but they can only develop into a limited number of 
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cell types to generate a specific tissue, a feature that is referred to as 
multipotency. The function of adult SCs is the replacement of dying cells 
(natural turnover e.g. the gut) and regeneration of damaged tissue (wound 
healing). Adult SCs have the capacity for self-renewal and are maintained 
during the life time of the host. During the last few decades various adult SC 
types have been identified. The first evidence for their existence was 
produced for SC originating from the bone marrow niche [76]. It was found 
that hematopoietic SCs were able to differentiate into any type of blood cell 
such as T cells, B cells, granulocytes, erythrocytes and mast cells when 
transplanted into irradiated mice [76]. The hematopoietic model was of 
great importance for the understanding of tissue development [77]. 
Subsequently, other types of adult SCs have been discovered in neuronal, 
epithelial, mesenchymal and epidermal tissues [11, 78, 79]. 
Various pathways are essential for the regulation of the self-renewal and 
differentiation capacity of SCs. A role for Notch signalling has been shown in 
neural SCs as well as in mouse prostate development [80, 81].  Das et al. 
2008 and Kalani et al. 2008 demonstrated that Wnt signalling was critical in 
retinal and neural SCs [82, 83]. Hedgehog and transcription factor B 
lymphoma Mo-MLV insertion region 1 (Bmi-1) have been shown to play a 
role in regulating the normal mammary gland [84]. During normal 
organogenesis these processes are strictly regulated. Importantly, the 
deregulation of self-renewal may be one of the key events leading to 
carcinogenesis [84].  
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Figure 1-6 Asymmetric cell division in SCs. SCs have the capability for self-renewal 
and differentiation. Upon division they create an identical daughter cell and a TA 
that undergoes differentiation. Reproduced from [75]. 
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1.3.2 The CSC model 
There are two main models for carcinogenesis. The stochastic model 
proposes that the tumour mass is homogenous. According to this theory 
every cell in the tumour has the same tumour forming potential [4]. The CSC 
model suggests that the tumour consists of a heterogeneous mass of cells 
[4]. Here, only a small subset of cells, the CSCs, are capable of initiating 
tumourigenesis [4].  The CSCs might develop from a deregulation in normal 
SCs that reside in the tissue e.g. prostate SCs. 
 Like normal SCs replenish their specific tissue, CSCs might form a reservoir 
that reconstitutes the tumour mass [4, 85]. They divide and expand the CSC 
pool and develop into heterogeneous cancer cells [85]. The main criteria 
that define CSCs are the capacity for self-renewal, differentiation, invasion, 
extensive proliferation and tumour initiating capacity [86-88]. The CSC 
model for the development of prostate cancer is presented in Figure 1-7.  
1.3.3 CSC types  
 A relationship between SCs and carcinogenesis was first shown in 1997 in 
acute myeloid lymphoma (AML) [88]. A population of cells expressing the 
markers CD34++CD38- initiated AML in NOD/SCID mice, whereas committed 
progenitor cells failed to engraft [88]. These cells showed major features of 
SCs, such as capacity for self-renewal, differentiation and high proliferative 
potential [88]. In the following years, CSCs were also identified in many solid 
tumours in the breast, lung, head and neck, pancreas, liver, kidney, colon, 
ovarian, brain bladder, endometrial and prostate [87, 89-103]. 
1.3.4 Characterization of prostate CSCs 
Normal human prostate SCs were first identified by experiments in a rat 
model that showed the regression of the prostate gland upon castration [4, 
12, 104]. The prostate could then be restored by hormone induction [4, 12, 
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105]. The observation that this cycle could be repeated multiple times led to 
the conclusion that a surviving castration-resistant SC population must exist 
[4]. Subsequently, normal human prostate epithelial SCs were identified in 
the normal/benign prostate using gland regeneration experiments: a basal 
epithelial phenotype of cells positive for CD133 and expressing high levels 
of α2β1integrin showed the highest clonogenic potential and gland 
regeneration in immuno-compromised mice [11, 106]. The same cellular 
phenotype was explored by Collins et al. 2005 to sub-fractionate epithelial 
cells from human prostate cancers [33, 87]. Prostate CSCs represented a 
very small fraction of the total tumour mass (approximately 0.1%) [4]. 
CD133 and α2β1integrinhigh cells isolated from primary cultures grown from 
prostate tumours had self-renewal, proliferative and differentiation 
properties in addition to invasiveness and an enhanced secondary colony 
forming efficiency, [33, 87]. The hierarchical and heterogeneous 
organization of the tumour mass suggests that CSCs give rise to the entire 
malignant tissue [107, 108].  
In order to compare transcription patterns a microarray analysis was carried 
out on SCs (CD133+/α2β1integrinhigh) and CBs (CD133-/α2β1integrinlow) from 
both benign and malignant prostate samples [33, 109]. A significantly 
different gene expression signature emerged in SCs compared to CBs [33, 
109]. More crucially, gene expression differences were found when 
comparing benign SCs to SCs originating from malignant tissues [33, 109]. 
The profiles revealed that the expression of 581 genes was significantly 
different in SCs from malignant tissues relative to benign control cultures 
[33, 109].  A number of the genes identified in the CSC signature were 
linked to carcinogenic alterations, including promotion of an invasive 
phenotype in prostate and other cancers [33, 109]. By using Gene Ontology 
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and the KEGG pathway database, functional associations and the activation 
of signalling pathways were identified in CSC relative to benign tissues [33, 
109].  For instance, malignant SCs expressed genes linked to inflammation 
such as IL-6 and NFκB activated genes [33, 109]. Furthermore, it showed 
that Wnt signalling, the JAK-STAT pathway and adhesion signalling 
pathways were upregulated in the CSCs [33, 109]. In prostate cancer Wnt 
signalling has been linked with both androgen-independence and bone 
metastasis [110-112].  
There are further studies that aimed to define prostate CSC markers e.g. 
TRA-1-60/CD166/CD151 cells [33, 113]. Like CD133+/α2β1integrinhigh cells, 
TRA-1-60/CD166/CD151 cells did not express markers associated with 
differentiated secretory luminal cells, AR or PSA [113]. They possessed 
major hallmarks of SCs such as multipotency as revealed by in vitro sphere-
formation and tumour-initiation in the mouse model [33]. However, the 
authors did not directly correlate the expression of TRA-1-
60/CD166/CD151 to CD133 expression [33]. Through analysis of 
microarray data from Birnie et al 2008 we know that the 
CD133+/α2β1integrinhigh SC populations also expressed TRA-1-
60/CD166/CD151 and constitute therefore potentially the same population 
[33]. Alternative or additional prostate SCs markers have been explored 
elsewhere [114]. 
1.3.5 CSCs as the origins of prostate cancer 
Originally prostate cancer was thought to develop from luminal cells [124]. 
This conclusion was mainly based on the underlying ratio changes in 
prostate cancer [124]. The luminal: basal compartments change from ~1:1 
in the normal prostate to a decrease of basal cells with the majority of cells 
having a luminal phenotype in malignant prostate tissue [33, 115, 116]. It 
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could be hypothesized that the luminal cells might have regained the 
function for self-renewal due to disruptions in cell signalling. For example a 
chromosomal translocation could generate a novel fusion protein, which 
reprogrammes a cell to express a self-renewal signature [117]. For instance, 
a mechanism that allows the transformation of a differentiated cell into a 
CSC has been identified in blast crisis chronic myelogenous leukaemia [85].   
However, several findings propose that the cell of origin of prostate cancer 
resides in basal compartment and the likelihood of de-differentiation from 
luminal to basal cells is slim [16, 106, 118-122]. In particular SCs are a very 
likely candidate for tumour initiation. SCs are maintained during the lifetime 
of the host, hence the probability for the accumulation of genetic alterations 
in the SC population causative for tumour development should be higher 
than in short-lived terminally differentiated luminal cells [33]. Furthermore, 
pathways necessary for SC maintenance e.g. Notch, Sonic hedgehog and Wnt 
signalling are associated with carcinogenesis [33, 74]. Alternatively, prostate 
cancer might originate from differentiated progeny which revert into a SC- 
like cells [107, 114, 115, 123, 124].  
However, support for a basal origin for prostate cancer has also been shown 
with mouse basal cells that developed into a tumour mass with a luminal 
phenotype after induction of ERG expression and activation of PI3K 
signalling [33, 118]. A similar result was seen with human benign prostate 
cells that were transduced with lentiviruses to introduce AKT, ERG 
transactivator and AR genes in luminal and basal cells [33, 119]. When 
transplanted into mice, only the basal cells were able to initiate tumour 
growth [33, 119]. Furthermore, the histological analysis of the tumour tissue 
revealed a reduced basal compartment, but an increased luminal 
compartment, which is a characteristic of human prostate tumours [33, 119]. 
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CSCs might not only be the source of cancer development, but also play a 
role in therapy resistance and tumour relapse. 
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Figure 1-7 The prostate CSC theory. Normal prostate SCs (green) differentiate into 
TAs and CBs (grey) that develop finally into differentiated prostate cells (white). 
According to the prostate CSC theory mutations in prostate SCs or TAs might lead 
to their transformation into CSCs (red). These differentiate into TAs and CBs and 
make up a heterogeneous tumour mass (yellow). Contrary to their healthy 
counterparts, malignant cells fail to grow into structured layers. According to the 
CSC theory all of these different cell types (red, yellow) are present in a tumour and 
the CSCs form the reservoir of undifferentiated cells from which all other cell types 
arise. Reproduced from [33]. 
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1.4 The DNA damage response 
In view of constant DNA damaging influences the maintenance of genomic 
stability is a major concern in all cells and a coordinated response to DNA 
damage is necessary to ensure the survival of the host [125]. To maintain 
genomic integrity the cell devotes a wide range of mechanisms such as DNA 
damage checkpoints, DNA repair pathways, apoptosis, senescence and 
autophagy. The DNA damage response is predominantly controlled by the 
regulators Ataxia-telangiectasia mutated (ATM) and ATM and RAD3-related 
(ATR) proteins, which belong to the phosphoinositide-3-kinase (PI3K)-
related protein kinases (PIKKs). The breakdown of these pathways is 
correlated with severe consequences for the host such as the development 
of cancer [125-128]. 
1.4.1 Sources of DNA damage 
DNA damage can originate from exogenous and endogenous sources. 
Endogenous DNA damage can be a result of oxidative reactions with 
surrounding water molecules, oxygen and reactive oxygen species (ROS) 
generated by metabolic byproducts [125]. The induction of exogenous 
damage can be the consequence of mutagenic chemicals or viruses [125]. 
Radiation is another source of exogenous DNA damage, including non-
ionizing radiation such as ultra-violet radiation (UV) and ionising radiation 
[125]. Ionising irradiation can arise from cosmic rays or earth bound sources 
[125]. The induction of exogenous DNA damage plays a critical role in 
chemo- and radiotherapy to kill cancer cells, even if ironically, exposure to 
DNA damaging conditions is linked to an increased cancer risk [125].  
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1.4.2 Introduction of DNA damage through chemicals for cancer 
therapy  
For many cancers, surgery and radiotherapy are not sufficient to eradicate 
the malignant cells or may not be able to function optimally due to the 
location of the tumour. For this reason chemotherapeutic drugs are 
preferable to increase the probability of a long-lasting tumour regression. 
Many chemicals used against cancer are replication inhibitors. These 
specifically target rapidly proliferating cells, as many cancer cell types are, 
and thereby interfere with the normal progression of the cell cycle leading to 
DNA damage and ideally cell death. The following paragraph introduces six 
different replication inhibitors that are related to experiments carried out in 
this thesis. All of them, except excess thymidine, are of relevance in the 
clinic for cancer treatment.  
The anti-cancer drug etoposide is a podophyllotoxin-derivative. Its 
mechanism relies on the production of strand breaks in DNA by inhibiting 
the enzyme topoisomerase II, which is important for unwinding DNA during 
replication [129]. The alkaloid camptothecin arrests the cell cycle by a 
similar mechanism as etoposide, but it inhibits topoisomerase I rather than 
topoisomerase II [130, 131]. Carboplatin is a derivate of cisplatin. Its exact 
mechanism of action is not known [132]. It causes platinium-DNA adducts 
leading to interstrand cross-link formation [132, 133]. Doxorubicin belongs 
to the group of anthracyclin-antibiotics. Its effect relies on two main 
mechanisms: firstly by intercalation into the DNA and thereby blocking 
transcription and secondly by directly blocking toposiomerase II [134, 135]. 
The taxane docetaxel inhibits cells during mitosis. It binds and stabilizes the 
microtubuli-apparatus thereby preventing progression through mitosis 
leading to cell cycle arrest [136]. Thymidine is not used for cancer therapy, 
but it is used for research purposes to trigger replication stress in cells. 
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Excess thymidine results in an increase of the intracellular dTTP pool and 
prevents supplement of dCTPs by allosteric regulation of ribonucleotide 
reductase [137, 138]. The resulting depletion of dCTP slows DNA synthesis 
and arrests cells in the S-phase [138].  
1.4.3 DNA damage induced signalling 
The DNA damage response is mediated through proteins of four main 
groups: sensors of DNA damage, mediators that enhance the signal 
generated through DNA damage and transducers that pass the signal to 
effectors which are responsible for the activation of cellular responses [125], 
(Figure 1-8). 
A master regulator in the response to DSBs is the protein ATM, which 
belongs to the PIKKs [139]. The pathways downstream of ATM have been 
frequently described, but the mechanism of DNA damage sensing itself and 
the steps involved in ATM phosphorylation are mostly unknown [125]. It has 
been shown that the generation of DSBs results in the recruitment of the 
Meiotic recombination protein-11 (MRE11)-RAD50-Nijmegen breakage 
syndrome protein-1 (NBS1) (MRN) complex and the transformation of the 
inactivated ATM dimer into the monomeric, phoshorylated form of ATM 
(phATM) [140, 141]. Activated ATM binds to the MRN complex on the sites 
of DNA lesions and activates the C-terminal region of the histone variant 
H2A.X by phoshorylation [141]. γH2AX (the phophorylated form of H2A.X) is 
capable of binding Mediator of DNA Damage Checkpoint Protein-1 (MDC1) 
and recruits additional ATM-MRN complexes leading to further H2A.X 
phosphorylation [141]. The expression of yH2A.X is one of the early events 
measured after the introduction of DNA damage. It is crucial for the 
recruitment of repair factors such as RAD50, RAD51 and the product of the 
gene BRCA-1 [142]. Due to its central role in DNA damage signalling γH2A.X 
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is often used as a marker to detect DNA DBS, but also SSB. Furthermore, its 
appearance has been described as a genotoxic endpoint for the cell [143]. 
Upon its activation, ATM phoshorylates multiple substrates and thereby 
causes cell cycle arrest. The cell can re-enter the cell cycle following DNA 
damage repair or if the damage is not recoverable, the cell can activate 
apoptosis or senescence [144-146].  
Another PIKK crucial in DNA damage signalling is ATR. The accumulation of 
single-stranded DNA (ssDNA) is the main trigger of the ATR-dependent 
checkpoint response [147]. It has been shown that in Xenopus egg extracts, 
the most developed model for this research, replication stress causes 
extended stretches of ssDNA [148, 149]. The generated ssDNA is then 
coated by RPA in an ATR-interacting protein (ATRIP) dependent manner 
[141, 150, 151]. ATRIP needs to be associated with the RAD9-RAD1-HUS 
complex that is able to detect and bind DNA ends adjacent to RPA-coated 
ssDNA [141, 152]. The RAD9-RAD1-HUS-Complex recruits topoisomerase-
binding protein-1 (TOPBP1) to sites of DNA lesions leading to an activation 
of ATR [141, 153, 154].  Activated ATR then phoshorylates checkpoint 
kinase Chk-1 on ser-345 and ser-317 [141, 155-157]. After dissociation of 
activated Chk-1 from the chromatin it phosphorylates a wide range of 
downstream targets [141]. Recently, ATR has also been shown to respond to 
DSB breaks [158].  
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Figure 1-8 The recruitment of proteins as response to DNA damage. The DNA 
damage response is coordinated by sensors, mediators, transducers and effectors, 
which lead to different cellular responses. Reproduced from [125, 159].   
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1.4.4 DNA repair 
Evolution has equipped the cell with several repair mechanisms that are 
capable of recognising and repairing distinct types of DNA damage [125]. 
From a simplified point of view DNA repair comprises three main processes: 
(i) recognition of DNA damage, (ii) excision or removal of the DNA damage 
and (iii) restoration of the DNA [125]. Depending on the type of DNA 
damage, cells initiate different types of repair mechanisms. Single 
nucleotide errors resulting from DNA damage or errors in DNA replication 
are repaired by base excision repair (BER), nucleotide excision repair (NER) 
or mismatch repair (MR) [125, 160]. BER is also used for the repair of SSBs. 
The more severe DSBs are repaired by non-homologous end-joining (NHEJ) 
or homologous recombination (HR) [125, 161, 162].  
1.4.4.1 BER/ SSB repair  
The BER pathway serves to eliminate fragmented or modified bases in DNA. 
BER is also used to repair SSBs, which can be generated endogenously by 
ROS or IR and the abortive activity of topoisomerase I and II [163-166]. 
There are two different variants of BER: the predominant short patch 
mechanism and the long patch mechanism (Figure 1-9). The first step in 
short patch BER is the removal of the base by a DNA Glycosylase, a process 
that leads to the generation of an Apurinic/apyrimidinic site (AP site) [125]. 
The APE1 endonuclease then incises the DNA strand (leading to a SSB) [167]. 
The detection of SSBs is predominantly via PARP1 [167]. PARP1 is 
responsible for the recruitment of XRCC1 to the sites of DNA damage [168]. 
XRCC1 is essential for the recruitment of factors that mediate end 
processing, gap filling (DNA polymerase β) and finally ligation (DNA ligase 
IIIα) [169, 168]. Long patch BER also requires the APE1 to cleave the DNA 
strand but depends on the factors PCNA, RFC and DNA polymerase δ or Ɛ 
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and DNA Ligase I for further processing [170]. Whereas in short patch repair 
only one nucleotide is “flapped” away from the strand in long patch repair a 
“flap” of 2-8 nucleotides is produced, which is excised by the flap 
endonuclease 1 (FEN1), [125, 170].  
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Figure 1-9 The mechanisms of BER repair. BER consists of a short patch and a long 
patch pathway. Both processes initiate with the generation of an AP site, but are 
then mediated by different types of proteins. Reproduced from [125, 170].  
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1.4.4.2 DSB repair 
DSBs are the most severe form of DNA damage as they can lead to the loss 
of genetic information [125]. DSBs can be generated by oxidative stress, IR 
and topoisomerase inhibitors [166, 171, 172]. DSBs can be repaired through 
NHEJ and HR. The main difference between the two pathways is that HR 
requires sequences of homologous DNA for the alignment of the broken 
ends, whereas NHEJ re-joins them without using homologous regions. The 
first step of NHEJ in mammals is the recognition and coating of broken DNA 
ends by the Ku70/80 heterodimer to prevent degradation [125, 173]. 
Ku70/80 is required for the recruitment of DNA-PKcs to the site of the lesion 
[174]. Potential overhangs are processed by Artemis and Polynucleotide 
Kinase (PNK) [125, 175, 176]. The strand gaps are then filled by DNA 
Polymerase ß [177]. DNA-PK (=DNA-PKcs associated with Ku70/80) recruits 
the XRCC4-DNA ligase IV which is essential for resealing the DNA [178]. A 
schematic presentation of NHEJ is shown in Figure 1-10. HR uses 
homologous DNA as a template to repair of DSBs. The mechanism is 
particularly associated with the S-Phase when sister chromatids are 
available. The first step of HR involves a 5´-3´resection of the DSB end 
which generates a 3´single stranded overhang [125, 179]. This produces 
ssDNA, which is coated by Rad51that is required for strand invasion [180, 
181]. The invasion leads to a displacement of the homologous DNA region 
and the subsequent generation of a D-Loop (D=displacement). This event 
creates an X-shaped structure known as Holliday junction [182]. DNA 
synthesis is then carried out using the homologous template by DNA 
polymerase Ɛ followed by a ligation step [125, 183]. A schematic 
presentation of HR is shown in Figure 1-11. 
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Figure 1-10 The mechanism of NHEJ. DSBs are repaired by NHEJ. DNA-PKcs, Artemis 
and Ku70/80 locate to the site of the lesion for end processing and gap filling. DNA 
ligase IV is required for the ligation. Reproduced from [125, 170].  
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Figure 1-11 The mechanism of HR. HR starts with a strand resection that creates a 
3’ overhang. The next step is coating by Rad51 (required for strand invasion) and 
Rad52 (function unknown). The strand invasion displaces a strand from the 
homologous region by the formation of a D-loop structure and a Holliday junction. 
The lost DNA sequences on both strands are restored and the resolution of the 
Holliday junction is then carried out by enzymes (resolvases) that produce nicks. 
Modified from [125, 170].  
 
 
                                                                                             INTRODUCTION 
55 
 
1.4.4.3 Regulation of DNA repair 
ATM is critical in the NHEJ pathway as it phosphorylates Artemis. ATM 
activates DNA- PKcs by phosphorylation on threonine-residue-2609, which 
is a stimulator for Artemis nuclease activity. ATM also functions in the HR 
pathway by phosphorylating many factors like BRCA1, c-ABl, Bloom 
Syndrome Protein, H2A.X, and NBS1[184]. Also, ATR signalling is critical for 
regulating the repair of various DNA lesions. It targets a wide range of 
proteins linked to recombination (BRCA1, Werner syndrome ATP-dependent 
helicase, Bloom syndrome protein) [185-188].  ATR and BRAC-1 play a role 
in the regulation of BER [189]. 
1.4.5 Cell cycle checkpoints 
The cell cycle of an eukaryotic cell can be divided into four stages: the Gap 
phase 1 (G1), synthesis of sister chromatid phase (S), Gap phase 2 (G2) and 
Mitosis (M). Cells that are out of cell cycle are in G0 and referred to as 
quiescent or dormant. The cell cycle is strictly regulated by cyclins and cell 
cycle checkpoints which control the order of these processes in cycling cells 
to ensure that a distinct event happens only after completion of a previous 
event [125, 190-193]. This is crucial, as for example cells need to be 
prevented from entering S-Phase when only an insufficient amount of 
nutrients are available or proceeding to mitosis before the complete 
duplication of the genome and other components (e.g. organelles) has 
occurred [125, 191-193]. In the presence of DNA damage, the induction of 
cell cycle checkpoints is a critical step as they allow time for cellular 
responses such as DNA repair or apoptosis [125]. The cell cycle checkpoints 
can be classified as G1/S, S, and G2/M  (Figure 1-12) [194]. In the presence 
of DNA damage the G1/S checkpoint serves to prevent the cell from 
entering S-phase by inhibiting initiation of replication to ensure genomic 
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stability [170, 194]. The intra-S-phase checkpoint is initiated by DNA 
damage that occurs during S-phase or by unrepaired lesions that passed the 
G1/S checkpoint [170, 195]. The intra-S-phase checkpoint it not capable of 
halting the DNA replication, but is able to slow the S-Phase by suppression 
of origin firing [195, 196]. The G2/M checkpoint serves to avoid mitotic 
entry of damaged cells [196]. Although these checkpoints are distinct, the 
DNA damage sensors responsible for their activation seem to be shared by 
all three pathways [170]. ATM and ATR play a central role in the regulation 
of checkpoints [170]. In the G1/S checkpoint ATM phosphorylates p53 and 
Chk2 [170]. These phosphorylations lead to the activation of two main 
pathways: one to initiate and one to maintain G1/S [170, 197]. The initiation 
is mediated by phosophorylation of Chk2, which phosphorylates Cdc25A 
phosphatase leading to its inactivation and proteolytic degradation leading 
to G1 arrest [170, 198, 199]. Alternatively to the ATM-Chk2-Cdc25A 
pathway (activated through IR) the initial arrest can also be caused by the 
ATR-Chk1-Cdc25A pathway (activated by UV light) [170]. P53 plays a role in 
mediating the maintenance of the G1/S arrest [197]. 
During the ATM-regulated intra-S-phase checkpoint, in response to DSBs, 
ATM triggers two parallel pathways. ATM phosphorylates Chk2 using MDC1, 
H2A.X and 53BP1 as mediators, which leads to the degradation of Cdc25A 
[170]. ATM can also initiate a second pathway by phosphorylating the 
proteins NBS1, SMC1, BRCA1 and FANCD2 [170]. Both pathways lead to a 
block of replication [170]. Furthermore, in response to SSBs there is a ATR-
Chk1-Cdc25A mediated pathway [170]. 
For the G2/M checkpoint the ATM-Chk2-Cdc25A or ATR-Chk1-Cdc25A 
pathway can be activated depending on the type of DNA damage [157, 200, 
201]. The proteins MDC1, 53BP1 and BRAC1 mediate the signal generated 
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through DNA damage to Chk2 and Chk1 and these regulate Cdc25A (Chk1, 
Chk2) and Wee1 (Chk1) leading to G2 arrest [170]. 
 
 
 
 
 
 
 
 
 
 
                                                                                             INTRODUCTION 
58 
 
          
Figure 1-12 The cell cycle including its checkpoints. The cell cycle can be divided 
into four stages: G1, S-phase (synthesis of sister chromatids), G2 and M-Phase 
(mitosis). Dormant or quiescent cells are in G0. Before the transition into the next 
stage of the cell cycle the cell passes cell cycle checkpoints (G1/S, S, G2/M). 
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1.4.6 Apoptosis 
In contrast to necrosis, a consequence of tissue injury, apoptosis is a 
programmed death induced by the cell to ensure the survival of the host. 
Apoptosis is an energy-dependent mechanism and is characterized by 
distinct morphological changes [202]. It plays a role in the normal cell turn-
over, development and function of the immune system, embryonic 
development and chemical-induced cell death [202]. Inappropriate control 
of apoptosis is causative for various human disorders including many types 
of cancer [202]. There are two major apoptotic signalling pathways: the 
extrinsic pathway that is mediated through the death receptor and the 
intrinsic mitochondrial pathway. The important apoptotic mechanism to 
eliminate DNA damaged cells is intrinsic apoptosis.   
The intrinsic pathway is initiated by signals such as the absence of growth 
factors, radiation, toxins, hypoxia and free radicals [202]. These conditions 
lead to changes in the inner mitochondrial membrane resulting in the 
opening of the mitochondrial permeability transition pore, the loss of the 
mitochondrial transmembrane potential and the release of pro-apoptotic 
proteins, such as cytochrome c, from the intermembrane space into the 
cytoplasm [202, 203]. Cytochrome c release can be initiated via the tumour 
suppressor p53 [202, 204]. Cytochrome c binds and activates Apaf-1 and 
procaspase 9, which is referred to as the apoptosome [202, 205, 206]. This 
triggers a caspase-cascade leading finally to programmed cell death to clear 
the host of defective cells [202, 204].  
The control and regulation of intrinsic apoptosis occurs through members of 
the Bcl-2 family of proteins [207]. To regulate apoptosis, ATM targets p53, 
the E3 ubiquitin ligase MDM2, Chk1and Chk2, H2AX and BRCA1 [208-211]. 
P53 is known to play a critical role in the regulation of the Bcl-2 family, even 
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if the mechanisms are not fully understood [212]. It is believed that the 
members of the Bcl-2 family are paramount for the regulation of 
cytochrome c release through modification of mitochondrial membrane 
permeability [202]. 
1.4.7 Autophagy 
Autophagy is a cellular stress response. Following autophagy cells can 
undergo apoptosis, or use it as a survival mechanism. Similar to apoptosis, 
autophagy could play an important role in human disease [202]. Autophagy 
is characterized by the sequestration of the cytoplasm and its organelles in 
membrane vesicles (autophagosomes) and subsequent transport to the 
lysosomes for degradation [202, 213]. In contrast to apoptosis, autophagy is 
a caspase-independent process [214]. A main trigger for autophagy are 
starvation conditions, where autophagy serves as a survival mechanism 
[215, 216]. Additionally, it can be caused by a range of chemotherapeutic 
agents [217]. It has been demonstrated that its induction is an escape 
mechanism, which prevents the cell from inducing apoptosis [218-220]. 
1.4.7.1 The mechanism of autophagy 
The first regulatory process of autophagy involves the de-repression of the 
mTOR Ser/Thr kinase, which inhibits autophagy by phosphorylation of 
Autophagosome-autophagy-related gene (AP-Atg) 13 [221]. AP-Atg 13 has 
been identified in yeast, but a mammalian homologue is not known at this 
time [221]. In mammalian cells the endoplastmic reticulum has been 
proposed as the source of the autophagosomal membrane [222, 223]. The 
autophagosome arises initially from a structure referred to as “phagophore”, 
where the cytoplasm or organelles are wrapped by a double membrane 
[215, 216]. The AP-Atg proteins, which are located in the membrane of the 
vesicles, play a major role in autophagosome formation [216]. In yeast the 
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AP-Atg proteins have been extensively studied and it has been 
demonstrated that they fulfil tasks in scaffolding the pre-autophagosomal 
structures and phagophore elongation [216, 224]. The autophagy gene 
Beclin 1 has been identified as an important factor that modulates the 
function of AP-Atg proteins [216]. In addition the membranous protein LC3-
II plays an important role in autophagosome formation [224]. The 
membranes enclose their contents in an non-specific fashion [216]. Upon 
sequestration, autophagosomes fuse with lysosomes to form autolysosomes 
and the cytoplasm derived materials are degraded by hydrolases [216]. 
Through this process macromolecules are degraded into monomeric units 
such as amino acids and are then transported to the cytoplasm for reuse 
[216]. The process of autophagosome formation is illustrated in Figure 1-
13. 
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Figure 1-13 The process of autophagy in mammalian cells. In the first step 
cytoplasm and organelles are included from the phagophore which closes to form 
an autophagosome. The autophagosome fuses with a lysosome to form an 
autolysosome that degrades the internal material for reuse. Modified from [216, 
225].  
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1.4.8 Senescence 
Cellular senescence is an irreversible cell cycle arrest that acts as a 
safeguard programme of the cell to reduce its proliferative capacity after the 
exposure to stress signals [226]. Hence, like apoptosis, cellular senescence 
has a tumour suppressor function [226]. A growing line of evidence 
suggests senescence as a critical mechanism in response to 
chemotherapeutic agents [226]. Whereas the “replicative senescence” is 
related to cellular aging and was found to be induced through DNA damage 
signals from eroded telomeres that shorten with each cell division, 
“premature senescence” is an acutely inducible form of senescence [226- 
228]. Both mechanisms are biochemically and morphologically highly related 
[226]. The cellular insults that cause “premature senescence” may include 
ROS, unresolved DNA damage, y-irradiation, and chemotherapeutic drugs 
[226, 229-234]. Agents that cause an acute senescence in tumour cells are 
considered as an option to force a terminal rest programme [226].  
However, in some experimental set ups this form of senescence has been 
shown to be reversible, therefore raising issues about its therapeutic effect 
in the long term [235, 236]. 
1.5 Therapy resistance of CSCs  
There are several factors that hamper a successful (prostate) cancer therapy. 
Among these are hypoxia, anti-apoptotic mechanisms, aberrant androgen-
receptor signalling, increased drug efflux through the expression of ABC-
transporters, detoxifying enzymes and cellular quiescence [33]. Recent 
findings link CSCs to therapy-resistance, in particular in relation to some of 
the mentioned resistance mechanisms (Figure 1-14). It is proposed that the 
CSCs are a therapy resistant fraction within the tumour that does not 
respond to conventional treatments and might therefore be responsible for 
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the recurrence of secondary therapy-resistant tumours [33, 100, 114, 237-
239]. Normal SCs harbour better protective and repair mechanisms against 
DNA damage [240-243]. This is essential for a cell type that maintains 
during the life time of an organism, and is, due to this time factor, more 
likely to accumulate genetic alterations [242]. The more effective shielding 
against DNA damage is crucial to fulfil their tasks in tissue regeneration 
properly without passing alterations to the daughter cells. It is likely that 
CSCs “hijack” these features and are therefore less responsive to DNA 
damage introduced by cancer therapy [237, 244, 245]. This raises the issue 
of how CSCs are better protected against treatment than more differentiated 
tumour cells.  
 1.5.1 Mechanisms of therapy resistance in CSCs 
A variety of mechanisms causal for treatment resistance in the CSC 
population have been proposed.  For instance, CSCs are believed to have an 
enhanced resistance to DNA damage. Normal SCs exhibit efficient DNA 
mutation defence systems. When mutations occur that transform SCs into 
CSCs these defence systems are thought to protect CSCs against 
chemotherapy and irradiation [246]. Two candidates responsible for the 
mediation of therapy-resistance in CSCs might be Chk1 and Chk2 that 
become activated after genotoxic stress and arrest the cell cycle to enable 
repair [246]. Chk1 and Chk2 have higher activities in SC compared to 
normal cells [247]. In regard to CSCs, inhibitors against Chk1 and Chk2 
partially reverse the resistance to irradiation in glioblastoma CSCs [247, 
248].  
Quiescence in cells is a critical mediator of treatment resistance, as most 
therapeutic strategies are designed to target rapidly proliferating cells. 
Indeed, many cancer treatments work initially for the majority of rapidly 
                                                                                             INTRODUCTION 
65 
 
proliferating primary tumour cells, but fail to eradicate quiescent 
populations. In particular, adult CSCs were shown to be in G0, a feature they 
might have inherited from their healthy counterparts [242]. Some studies 
already demonstrated that quiescent CSC populations e.g. from the colon, 
breast, ovaries, and pancreas harboured both in vitro and in vivo abilities to 
resist therapies that killed the main bulk of tumour cells [242, 249-251]. 
Hence, unsurprisingly the type of cell leading to initiation of secondary 
tumours must be the surviving CSC pool that re-enters cell cycle to re-
populate the tumour by giving rise to extensively proliferating TAs [242].  
Another factor correlated to therapy-survival of CSCs are ROS defence 
enzymes. ROS such as superoxide, hydrogen peroxide, hydroxylradical and 
nitrous oxide are produced in vivo as a result of normal metabolism [252]. 
They have influence on carcinogenesis, cardiovascular disease and ageing as 
they cause oxidative damage to proteins, lipids and DNA [252]. 
Peroxiredoxins are highly conserved enzymes that function to scavenge 
ROS. Their loss is associated with a tumour prone phenotype due to 
accumulation of damaged DNA [253]. Peroxiredoxins are thought to be key 
players in radio- and chemoresistance of cancer cells, as ROS are mediators 
of these therapeutic strategies. In a work of Diehn et a. 2009 CSCs  derived 
from the breast were demonstrated to express higher levels of ROS defence 
enzymes in comparison to their more differentiated counterparts which were 
correlated with radioresistance [254]. Lower ROS levels have also recently 
been reported for central nervous system SCs and haematopoietic SCs as 
well as their early progenitors [255-261].  
The family of ATP-binding cassette transporters (ABC-transporters) 
transport a large variety of substrates through the membrane, including 
metabolic byproducts, lipids, sterols and drugs. One of their main functions 
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is to expel toxins from the liver, kidneys and gastrointestinal tract. Due to 
their capability to excrete undesired substances, ABC-transporters are 
thought to play a critical role in chemotherapeutic agent resistance. Three 
types are mainly correlated with drug resistance: P-gp (ABCB1/multi-drug 
resistance (MDR) 1), MDR-associated protein (MRP1/ABCC1) and breast 
cancer resistance protein (BCRP/ABCG2). Their expression in different types 
of tumours has been correlated with a poor clinical outcome [262]. One 
frequently observed characteristic of CSCs is a high expression of ABC-
transporter proteins in comparison to more differentiated cells, which led to 
the definition of the so-called “side population” (SP). There are various 
studies that link the expression of ABC-transporters to enhanced resistance 
properties of CSCs e.g. in the brain, lung, breast and prostate [263-267]. 
The aim of many anti-cancer therapies is to trigger apoptosis. CSCs seem to 
be less sensitive to the induction of apoptosis by cytotoxic agents and 
radiation therapy compared with more differentiated tumour cells [244, 
268]. This might be due to Akt pathway activation and the overamplification 
of anti-apoptotic proteins such as those of the Bcl-2 family [246, 269]. 
Another important inhibitor of apoptosis in CSCs and promising target for 
cancer therapies is the transcription factor NFĸB [246]. In neural SCs it has 
been demonstrated that they are protected from undergoing apoptosis due 
to the absence of caspase-8 and overexpression of PED (Phosophoprotein 
Enriched in Diabetes over-expression) [270]. Also the expression of the 
cytokine IL-4 seems to be paramount for mediating drug resistance by 
inhibition of apoptosis [271, 272]. 
Furthermore, it has been reported that the reactivation of (developmental) 
signaling cascades including EGF/EGFR, SCF, Sonic hedgehog, Notch and/or 
Wnt/β-catenin seems to play a major role [244, 268, 273].   
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Finally, CSCs are not only believed to escape many therapeutic approaches, 
it is even thought that they may enrich after the induction of therapy by 
selecting for resistant CSC subpopulations within a heterogeneous CSC pool 
[246]. Evidence for radiation-induced enrichment has already been shown 
for both brain and breast CSCs [246]. Due to these findings, specific 
targeting of CSCs must be considered for improving current anti-cancer 
strategies with the aim of sensitizing tumours toward conventional therapies 
and effectively abrogating tumourigenesis. So far only very little is known 
about therapy-resistance of SCs derived from prostate cancer tissue. A more 
profound knowledge about their nature might be the key for the 
development of new treatment strategies to eradicate prostate tumours on 
the long-term. The elucidation of these mechanisms is paramount for our 
understanding of treatment resistance.    
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Figure 1-14 Mechanisms leading to therapy-resistance in CSCs. Note that the 
expression of ABC-transporters applies only to chemoresistance. Modified from 
[246]. 
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Aim and strategy of the study 
It was the aim of this study to investigate the therapy-resistance potential of 
CD133+ α2β1/ integrinhigh SCs derived from malignant and benign prostate 
tissues in comparison to CD133- α2β1/ integrinhigh TAs and CD133-
α2β1/integrinlow CBs originating from the same tissue. For this purpose 
epithelial cells were isolated from prostate tissues and expanded in culture 
to enrich subsequently for the above mentioned cell populations. The 
project aimed to answer two main questions: 
Are SCs more resistant to the induction of DNA damage than TAs and CBs?   
 The extent of DNA damage was assessed after treatment of the 
different populations with the “model drug” etoposide.  We used 
alkaline comet assays as a direct measurement of DNA damage and 
staining for the repair factor γH2A.X as an indirect measurement, 
both of were analysed by immunofluorecence microscopy. 
 The recovery of selected populations after etoposide treatment was 
examined by clonogenic assays. 
What might be the mechanisms of potential therapy-resistance in SCs? 
 The expression of ABC-transporters is a frequently reported therapy-
resistance mechanism of cancer cells. In particular CSCs were 
demonstrated to be highly capable of expelling undesired 
substances. We re-analysed a microarray data set for the expression 
of ABC-transporters at mRNA level in our prostate epithelial cell 
model. To conduct a functional analysis we incubated the cells with 
the fluorescent substance calcein and measured the change of calcein 
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levels by the plate reader to compare the effectiveness of the ABC-
transporters. 
 Another likely mechanism of resistance to treatment is cellular 
dormancy or quiescence, as chemotherapeutic drugs are mainly 
designed to target rapidly proliferating cells. Cellular dormancy was 
assessed by staining for the protein Ki67 and subsequent assessment 
by immunofluorescence microscopy.  
 The failure of apoptotic mechanisms is a common problem in cancer 
cells. Hence, we assessed apoptotic cell death following etoposide 
treatment by staining for activated caspases and examination by flow 
cytometry. Furthermore, we stained for LC3B to elucidate autophagy 
as an alternative cellular response. We assessed cell viability in 
prostate cancer cells following drug treatment using MTS. 
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2. MATERIALS AND METHODS 
2.1 General Methods 
2.1.1 Human prostate tissue processing and culture  
Prostate tissue was taken with approval from York and Hull Research Ethics 
Committee from patients undergoing transurethral resection of the prostate 
(TURP) and open or laparoscopic radical prostatectomy operations (ORP and 
LRP respectively). Diagnosis, age and treatment of the individual patients are 
listed in Table 2-1 and 2-2. Epithelial cells were isolated as described by 
[11]. Briefly, prostate tissue was washed with PBS, chopped and digested in 
collagenase for 12 h at 37°C on a shaker to release epithelial structures 
(acini and ducts).  Epithelial cells were separated from stromal cells by 
repeated gravity centrifugation at 100 g, RT, 1 min. The material was 
resuspended in trypsin and left for 30 min at 37°C on a shaker. Epithelial 
cells were transferred to 10 mm BioCoat TM Collagen I plates and co-
cultured with a confluent layer of irradiated STO feeder cells in stem cell 
media (SCM) at 37°C.  
2.1.2 Maintenance of primary cell cultures 
 Prostate epithelial cells were grown in co-culture with irradiated STO feeder 
cells in SCM on 10 mm BioCoat TM Collagen I  plates  at 37°C. Culture media 
was replenished every second day. For subculture, cell cultures were 
trypsinized as explained in 2.1.3 and pelleted at 200 g, RT, 5 min. Cells 
were resuspended in SCM and transferred to BioCoat TM Collagen I cellware 
and grown at 37°C. Cells were subcultured at a ratio of 1:2, 1:3 or 1:4 
depending on their growth. 
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2.1.3 Harvesting of primary cells and cell lines 
When epithelial cells reached approximately 80% confluency, culture 
medium was removed and cells were washed once with PBS and treated with 
1 ml trypsin for 1 min. Trypsin was blocked with R10. The procedure was 
repeated to remove the entire population from the plates. 
2.1.4 Cryopreservation  
For storage in liquid nitrogen, cells were trypsinized as explained in 2.1.3, 
pelleted at 200 g, RT, 5 min and resuspended in cold freezing media (FM) at 
a concentration of 1 - 2 x 106 cells/ ml. Cells were aliquoted in cryovials and 
stored at - 80°C for at least 24 h prior to transfer into liquid nitrogen. To 
culture from frozen stocks cells after freezing, cells were plated with 
irradiated STO feeder cells in 10 ml SCM. The media was replenished after 
24 h to remove the DMSO-containing freezing media from the culture. 
2.1.5 Preparation of STO feeder cells 
STO fibroblasts were grown on T175 plastic flasks. When they reached 
approximately 80-90% confluency they were trypsinized and pelleted at 200 
g, RT, 5 min. Cells were washed with PBS and resuspended in 10 ml SCM per 
100 cm2 of culture surface. Cells were transferred into universal tubes and 
treated with an γ-irradiation dose of 60 Gy to inactivate mitosis. Cells were 
stored at 4°C and used within 4 days. 
2.1.6 Selection of SCs, TAs and CBs from primary cell cultures 
Human prostate epithelial cells were harvested as described in 2.1.3. Cells 
were washed once in MACS buffer at 200 g, RT, 5 min and resuspended in 5 
ml SCM. To separate α2β1low cells (CBs) from the α2β1 high population (SCs and 
TAs) 10 mm BioCoat TM Collagen I plates were blocked with blocking 
solution at 37°C for 1 h. The blocking solution was removed and plates were 
washed once with PBS. Cells were incubated on the blocked plates at 37°C 
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for 20 min. α2β1low cells do not adhere within the indicated incubation time 
and can be collected easily from the plate afterwards. The plates were 
washed once with PBS. The α2β1high population was released from the plates 
by repeated trypsinization as described in 2.1.3. CD133+/α2β1 high SCs and 
CD133-/ α2β1high TAs were separated by a CD133 Cell Isolation Kit. Up to 
108 cells were resuspended in 300 µl MACS buffer, 100 µl FcR blocking 
reagent and 100 µl CD133 antibody microbeads. Sorting using MACS MS 
columns was then carried out in accordance with the manufacturers’ 
instructions.  Briefly, each magnetic column was used for approximately 6 x 
106 cells. After elution of the cells from the first column up to 4 ml of the 
CD133+ elute was passed through a second column to increase the purity of 
the population. 
2.2 Single cell analysis  
2.2.1 Immunocytochemistry for γH2A.X foci and Ki67  
The different cell subpopulations were selected as described in 2.1.6 (or 
used unselected depending on the type of experiment). Cells were plated on 
collagen I-coated 8-well chamber slides (10 000 for CBs and TAs; for SCs a 
lower number depending on the yield). For the γH2A.X staining, cells were 
incubated with 30 µM etoposide for 30 min or 45 min to induce DNA 
damage. Additional time points with etoposide were carried out to assess 
repair by removing the drug, washing once with PBS and leaving the cells at 
37°C for additional 24 h in SCM. A small set of samples were treated with 2 
mM thymidine at 37°C for 24 h to induce replication stress. For the Ki67 
staining cells were left untreated. 
The following volumes were applied per 8-well chamber slide: After removal 
of the medium, cells were washed with 1 ml PBS and fixed in 1.6 ml 
Fixation-Permablization buffer at RT for 15 min.  Cells were washed with 1 
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ml PBS. Cells were washed with 1.6 ml 0.5 % Nonidet-P40 (NP40) in PBS at 
RT for 20 min to remove cytoplasmic proteins and subsequently washed 
with PBS. The primary antibody anti-human γH2A.X was diluted 1: 1000 in 
0.5% BSA in PBS and cells were incubated in 1.6 ml at 4ºC o/n. After removal 
and washing three times with PBS, 1.6 ml of the secondary antibody goat 
anti-mouse Alexa Green 488 was added in a 1:1000 dilution in 0.5% BSA in 
PBS and incubated at RT for 45 min in the dark. The chambers were 
removed from the chamber slides and DNA was labelled with DAPI. A 
coverslip was mounted on the slides and fixed in place with nail polish. 
γH2A.X was detected by immunofluorescence microscopy. For analysis ~100 
cells (but at least 50 cells) were counted per well and the % of γH2A.X 
positive cells was determined. For the Ki67 staining the same procedure was 
applied. In this case a goat anti-rabbit Alexa Red 568 served as a secondary 
antibody. 
2.2.2 LC3B staining 
Primary cells were harvested as described in 2.1.3 and plated on collagen I-
coated 8-well chamber slides. After incubation with 60 µM etoposide for 60 
h, cells were washed once with PBS and incubated in fixation buffer for 15 
min. The cells were washed three times with PBS and permeablized in 0.25% 
Triton-100 in PBS for 10 min. Cells were washed three times with PBS and 
blocked with IF-blocking buffer for 1 h. The LC3B antibody was diluted in 
0.1% Tween 20/ 0.1% BSA in PBS and left on the cells for 1 h. Cells were 
washed three times with PBS and incubated for 45 min with a 1: 1000 
dilution of goat-anti-rabbit Alexa 488 in 1% BSA in PBS. Cells were washed 
three times with PBS and mounted with DAPI for final assessment by 
immunofluorescence microscopy.  
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2.2.3 Alkaline Comet Assay  
Primary cells were harvested according to 2.1.3. Cells were selected 
according to 2.1.6 (or left unselected depending on the type of experiment). 
30 000 cells (for SCs less depending on the yield) were treated per tube in 1 
ml etoposide in suspension while rotating on a MACS spinner at 37ºC. The 
etoposide concentrations ranged from 30 µM to 250 µM and the incubation 
times from 30 min to 3 h. After treatment, cells were pelleted at 200 g, RT, 
5 min and resuspended in 25 µl PBS. The following steps were carried out in 
the dark: Tubes were placed in a waterbath at 37ºC and 225 µl low melting 
agarose was added per tube. Samples were dropped onto agarose-coated 
slides and covered with coverslips. Slides were cooled for 15 min at 4ºC. 
Coverslips were removed and immersed in lysis buffer o/n. The following 
day, samples were placed into alkaline electrophoresis buffer and incubated 
for 40 min at 4ºC. Slides were run in a gel tank apparatus in alkaline 
electrophoresis buffer at 24 V (300 mAmps) for 40 min and drained 
afterwards. Samples were placed in neutralizing buffer for three times for 10 
min. To stain the samples SYBR-Gold was diluted 1:10 000 in TE buffer pH 
7.5 and 300 µl was added to each slide and covered with a coverslip. 
Samples were assessed by immnofluorescence microscopy and images of ~ 
100 cells per sample were taken to be analyzed with the comet analysis 
software TriTek – CometScore Version 1.5. 
2.2.4 Neutral Comet Assay  
Cells were harvested according to 2.1.3. Unselected populations were used 
or cells were selected according to 2.1.6.  30 000 cells per tube (for SCs less 
depending on the yield) were treated in 1ml etoposide in suspension while 
rotating on a MACS spinner at 37ºC. The etoposide concentrations ranged 
from 30 µM to 1mM and the incubation times from 30 min to 3 h. After 
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treatment cells were pelleted at 200 g, RT, 5 min and resuspended in 25 µl 
PBS. The following steps were carried out in the dark: Tubes were placed in 
a waterbath at 37ºC and 225 µl low melting agarose was added per tube. 
Samples were dropped onto agarose-coated slides and covered with 
coverslips. Slides were cooled for 15 min at 4ºC. Coverslips were removed 
and immersed in lysis buffer o/n. The following day samples were placed 
into TBE electrophoresis buffer for 10 min. Slides were run in a gel tank 
apparatus in TBE electrophoresis buffer at 24 V for 20 min and drained 
afterwards. To stain the samples, SYBR Gold was diluted 1:10 000 in TE 
buffer pH 7.5 and 300 µl were added to each slide and covered with a 
coverslip. Samples were assessed by immunofluorescence microscopy and 
images of ~ 100 cells per sample were taken to be analyzed with the comet 
assay analysis programme TriTek – CometScore Version 1.5. 
2.3 Caspase Assay 
Cells were treated in culture with etoposide. The etoposide concentrations 
ranged from 15 µM to 125 µM and the incubation times from 12 h to 72 h. 
The supernatant was collected and cells were harvested according to 2.1.3. 
Cells were washed in 2 ml cold MACS per sample and centrifuged at 200 g, 
RT, 5 min. Cells were washed in 2 ml cold MACS buffer per tube and 
pelleted at 200 g, RT, 5 min. The CaspACE™ FITC-VAD-FMK In Situ Marker 
was diluted 1:500 in PBS and cells were resuspended in 100 µl per tube and 
incubated for 20 min at 37ºC. Cells were washed in 2 ml PBS per tube and 
pelleted at 200 g, RT, 5 min. Cells were resuspended in 500 µl PBS. Caspase 
activity was assessed by a CyAn Flow Cytometer (Dako). 
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2.4 Plate reader experiments 
2.4.1 Calcein efflux test  
Epithelial cells were harvested according to 2.1.3 and selected according to 
2.1.6 (or used unselected depending on the type of experiment). 1000-20 
000 cells were plated on collagen I-coated 96-well plates and left to adhere 
for 2 h at 37ºC in KSFM. CBs and TAs were seeded as triplicates whereas for 
SCs the yield was only sufficient for one well. KSFM was removed and 200 µl 
1:5000 Calcein- AM Fluorescent Dye in KSFM was added per well and left for 
15 min at 37ºC. Calcein AM Fluorescent Dye was removed. The wells 
containing the plated cells were washed with once in PBS and 200 µl KSFM 
without Calcein AM Fluorescent Dye were added per well. The plates were 
measured in the plate reader immediately and kept at 37ºC afterwards. After 
1 h the KSFM (containing effluxed calcein) was taken from the cells and cells 
were washed with PBS. Fresh KSFM without Calcein Fluorescent Dye was 
added to the cells. This step was repeated after 2 h and 3 h. Plates were 
measured at all indicated timepoints.  
2.4.2 Viability assay 
Cells were harvested as described in 2.1.3 and transferred to collagen I-
coated 96-well plates (5000 cells/ 100 µl SCM per well) After 24 h at 37°C 
media was removed and replaced by 100 µl fresh SCM containing a dilution 
series of replication inhibitors (see appendix). After four days, cells were 
measured by using the CellTiter96® Aqueous One Solution Cell Proliferation 
Assay. 20µl of solution was added and after 2 h incubation absorbance was 
measured. 
2.5 Clonogenic recovery assay 
TAs and SCs were selected as described in 2.1.3. 100 - 300 cells per well 
were seeded in triplicate on collagen I-coated 6-well plates in 2 ml SCM per 
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well and kept at 37ºC.  Cells were left for 2 h to adhere and washed once 
with PBS to remove floating cells. Fresh SCM was added to each well. The 
number of cells was then counted in every well. 500 µl irradiated feeder 
cells were added. Cells were treated for 45 min or 3 h with 30 µM etoposide 
or the appropriate dilution of DMSO at 37ºC. Cells were washed twice with 
PBS and 3 ml SCM were added to each well. Cells were kept at 37ºC and SCM 
was changed every second day. An appropriate amount of irradiated feeder 
cells was added to keep the plates confluent. After 8-14 days SCM was 
removed and cells were washed once with PBS. Cells were stained with 2 ml 
crystal violet solution per well for 20 min.  Cells were washed twice with 3 
ml PBS per well. The number of colonies was determined and related to the 
cells counted on the day of the selection. Different sizes of colonies were 
classified: colonies consisting of 2-4, 5-8, 9-16, 16-32 cells and > 32 cells. 
2.6 Malignant and benign prostate tissue samples and cell lines 
Sample (site) Diagnosis Age Surgery GS PT 
H020/09 Cancer n/a RP 3+4=7 - 
H035/11 (LA) Cancer 
T2c 
n/a RP 3+4 =7 
 
- 
H049/11 (LB) 
 
Cancer/ side 
carcinoma 
T2c 
n/a 
 
RP 
(ORP) 
 
3+3=6 
 
- 
PE665 Cancer 53 RP 3+4=7 - 
PE531 Cancer 57 RP 4+5=9 - 
H054/11 (RA) 
 
Cancer 58 
 
RP 
(LRP) 
3+4=7 
 
- 
H018/09 
 
Cancer 
HGPIN T2c 
n/a 
 
RP 
 
1 - 
H034/11  Cancer 
T3a 
 RP  3+4=7 
 
- 
H031/10 Cancer 
T2a 
n/a 
 
RP 
 
3+4=7 
 
- 
H048/11 (LM) Cancer 
 
n/a 
 
RP  3+3=6 
 
- 
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H149/12  Cancer 78 TURP N/A Hormone 
therapy 
Y018/11 Cancer 75 TURP 3+=6 Hormone 
therapy 
H090/09 Cancer 80 TURP 4+5=9 Hormone 
therapy 
H087/11 (LB)  Cancer 68 RP 
(ORP) 
3+4=7 
 
- 
H131/11 (LA) Cancer 70 RP 
(LRP) 
3+4=7 
 
- 
H069/11 (RB) Cancer 65 RP 
 
4+3=7 
 
- 
Y062/11 Cancer 61 TURP 
 
5+4=9 
 
Hormone 
therapy 
Table 2-1 Prostate carcinoma tissue 
Abbreviations: TURP = Transurethral resection of the prostate; GS = Gleason score; 
PT = Previous treatment; RP = Radical prostatectomy;  LRP = Laparoscopic radical 
prostectomy; ORP = Open radical prostatectomy; HGPIN = High grade prostate 
intraepithelial neoplasia; Tumour stages: T2a = tumour in half or less than half of 
the 2 lobes, T2c = tumour in both lobes; T3a = tumour has spread through the 
capsule; Sites the cores were taken from:  RA, LA, LM, LB, RB → R = Right, L = Left, 
A = Apex, M = Mid, B = Base 
 
 
Sample Age Surgery GS PT 
Y004/09 77 TURP - - 
Y031/08 83 TURP - - 
Y024/08 72 TURP - - 
Y040/09 67 TURP - - 
Y025/09 84 TURP - - 
Y010/11 61 TURP - - 
Y031/11 80 TURP - - 
Y052/10 72 TURP - - 
Y040/10 67 TURP - - 
H053/11 n/a TURP - - 
Y025/11 75 TURP - - 
Y030/11 88 TURP - - 
H053/11 N/A TURP - - 
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Y023/09 88 TURP - - 
Y075/11 80 TURP - - 
Table 2-2 BPH Tissue samples 
Abbreviations: TURP = Transurethral resection of the prostate; GS=Gleason 
score; PT = Previous treatment 
 
 
Cell line Origin Media Dilution upon 
subculture  
RC165N/hTERT 
[274] 
Benign prostate derived cell line R-Media 1:5 
RC92a/hTERT 
[274] 
Malignant prostate derived cell 
line 
R-Media 1:5 
PNT1a Normal prostate epithelial cell line R10 1:5 
LNCaP Human prostatic adenocarcinoma 
metastatic site in supraclavicular 
lymphnode 
R10 1:5 
BPH-1 Benign prostate derived cell line R5 1:10 
PC3 Human prostatic adenocarcinoma 
metastasis site in the bone 
H7 1:5 
STO Mouse embryonic fibroblasts D10 1:10 
Table 2-3 Mammalian cell lines 
2.7 Chemicals 
Drug Company 
Etoposide Sigma 
cat. no. E1383 
Carboplatin Sigma 
cat. no. C2538 
Docetaxel Fluka 
cat. no. 01885-25MG-F 
Doxorubicin Fluka 
cat. no. D1515-10MG 
Camptothecin Sigma 
cat. no. 365637 
Thymidine Sigma 
cat. no. T9250 
Table 2-4 Chemotherapeutic drugs 
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Kit/ Reagent Dilution 
 
Company 
BD TMCalcein AM Fluorescent Dye 
 
1:5000 BD Bioscience 
cat. no. 354216 
CaspACE™ FITC-VAD-FMK In 
Situ Marker 
1:500 Promega 
cat. no. G7461 
Mounting Medium with DAPI - Vectashield Laboratories 
cat. no. H-1200 
NuSieve® GTG® Agarose - Cambrex 
cat. no. 50080 
SYBR-Gold nucleid acid gel stain 1:10 000 Invitrogen 
cat. no. S11494 
CD133 Microbead Kit - Miltenyi Biotec Ltd 
cat. no.  130-050-801 
Collagenase Type I - Worthington 
cat. no. MX1H12791 
FCR blocking reagent - Miltenyi Biotec Ltd 
cat. no. 130-059-901 
DMSO - Sigma-Aldrich 
cat. no. D8418 
CellTiter96® Aqueous 
One Solution Cell Proliferation Assay 
- Promega 
cat. no. G3582 
Trypsin-EDTA - Gibco 
cat. no. 15400-054 
FCS - PAA 
cat. no. A15-041 
Goat serum - Sigma 
Cat.  No R4505 
Rabbit serum - Sigma 
Cat.  No G6767 
Table 2-5 Kits and reagents 
 
Antibody Host 
 
Reactivity Dilution Company 
γH2A.X 
 
mouse anti-human 1:1000 Millipore 
cat. no. 05-636 
Ki67 rabbit anti-human 1:1000 Abcam 
cat. no. ab15580 
CD133/2 (293C3)-APC mouse anti-human 1:11 Miltenyi Biotec 
cat. no. 130-090-854 
Alexa 568 goat anti-rabbit 1:1000 Invitrogen 
cat. no. A11036 
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Alexa 488 goat anti-mouse 1:1000 Invitrogen 
cat. no. A11029 
LC3B rabbit anti-human 1:1000 Abcam 
cat. no. ab51520 
Table 2-6 Antibodies 
Solution Components 
PBS 
 
137 mM NaCl 
2.7 mM KCl 
4.3 mM Na2HPO4 
1.47 mM KH2PO4 
Adjust to a final pH of 7.4 
Neutralizing Buffer 0.4 M Tris  
in  dH2O; adjusted to pH 7.5 
MACS buffer 0.5% FCS 
2 mM EDTA 
in PBS 
Lysis buffer 2.5 M NaCl 
1 mM EDTA 
10 mM Tris 
10% DMSO 
1% Triton X-100 
in dH20; adjusted to pH 10 
Alkaline electrophoresis buffer 0.3 M NaOH 
1 mM EDTA 
TE buffer 1 M Tris – HCl 
0.5 mM EDTA 
adjusted to pH 8 
Fixation-Permablization buffer 
(for nuclear stainings) 
 
2% PFA  
0.2% Triton x-100 
PBS 
adjusted to pH 8.2 
Fixation buffer 
(for staining proteins in the cytoplasm) 
3% PFA in PBS 
adjust to pH7 
TBE electrophoresis buffer 89.15 mM TRIS 
89.9 mM Boric Acid 
3.98 mM EDTA 
IF-Blocking Solution 
(LC3B staining) 
5% goat serum  
0.1% Tween 20 in PBS 
Blocking solution 
(selection of epithelial cells) 
0.3% BSA in PBS 
 heat-inactivated at 80°C for 10 minutes 
Crystal violet solution PBS 
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1% crystal violet  
10% ethanol 
Table 2-7 Solutions 
2.8 Media and plastic ware 
Media Components Origin 
RPMI 1640 --- 
 
Gibco, cat. no. 31870-074 
DMEM ---- Gibco, cat. no. 41966-029 
KSFM --- 
 
Gibco, cat. no. 17005-075 
Ham´s F-12  ---- Lonza, BE12-615F 
R5 RPMI 1640 
5% FCS 
as mentioned above 
as mentioned above 
R10 RPMI 1640 
10% FCS 
as mentioned above 
as mentioned above 
D10 DMEM 
10% FSC 
as mentioned above 
as mentioned above 
H7 HAM´s F-12  
7% FCS 
as mentioned above 
as mentioned above 
R-Media 500 ml KSFM 
5ng/ml Epidermal growth factor 
50µg/ml Bovine pituitary extract 
2mM L-Gluatmine 
as mentioned above 
as mentioned above 
as mentioned above 
as mentioned above 
SCM KSFM 
5 ng/ml Epidermal growth factor 
50 µg/ml Bovine pituitary extract 
2 ng/ml LIF 
2 ng/ml SCF   
100 ng/ml Cholera toxin  
1 ng/ml GM-CSF 
2 mM L-Glutamine 
as mentioned above 
Gibco, cat. no. 10450-013 
Gibco, cat. no. 13028-014 
Millipore, cat. no. LIF 2010 
First link, cat. no. 62-64-
206 
Sigma, cat. no. C8052-1MG 
Miltenyi,  
cat. no. 130-093-8865  
Gibco, cat. no. 25030-024 
FM  RPMI 1640 
20 % FCS 
10 % DMSO 
as mentioned above 
as mentioned above 
as mentioned above 
Table 2-8 Mammalian cell line culture media 
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Plastic ware Company 
20 x 10 mm BioCoat TM Collagen I   BD Biosciences 
cat. no. 356450 
Collagen coated 6-well plates BD Biosciences 
cat. no. 354400 
Collagen coated 8-well chamber slides BD Biosciences 
cat. no. 354630 
Collagen coated 96-well plates BD Biosciences 
cat. no. 356407 
T75 flasks Corning Incorporated 
cat. no. 430641 
MS columns Miltenyi Biotec Ltd 
cat. no. 130-042-201 
Table 2-9 Plastic ware 
2.9 Statistical Analysis 
The statistical analysis was conducted by Sigma plot 11.0. For paired t-test 
or  Wilcoxon rank sum test, values were considered to be significant when p 
< 0.05. 
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3. RESULTS 
3.1 Assessment of DNA damage in primary prostate epithelial 
cells using comet and γH2A.X assays 
The extent of DNA damage in cancer cells after their exposure to therapy is 
an important indicator to elucidate their treatment susceptibility. We used 
etoposide - a drug that also has clinical relevance for the treatment of many 
cancers - as a “model drug” for our studies. In order to compare levels of 
DNA damage in selected malignant and benign prostate populations, we 
treated cells with etoposide and employed comet and γH2A.X assays. 
3.1.1 Assessment of the DNA damage after etoposide treatment by 
comet assays  
3.1.1.1 Examination of the suitability of neutral and alkaline comet 
assays to detect etoposide-induced DNA damage 
Comet assays rely on the separation of damaged DNA (“tail”) from intact 
DNA (“head”) by gel electrophoresis, imaging of “comets” by 
immunofluorescence microscopy and the subsequent quantification of DNA 
damage e.g. by the  parameter % of DNA in tail (Figure 3-1). Both neutral 
and alkaline comet assays were performed to examine which technique was 
most suitable for detecting etoposide-induced DNA damage. In general, 
neutral comet assays are more specific for the detection of DSBs, but less 
sensitive than alkaline comet assays, which allow the quantification of DSBs, 
SSBs and alkali-labile sites [275]. Use of comet assays to assess etoposide-
induced DNA damage has been carried out before [166, 275]. However, the 
effect on primary prostate epithelial cells has not been measured. This was 
clearly of relevance in these studies. In order to verify whether neutral comet 
assays were suitable, we treated PNT1A cells and selected primary cells 
(H020/09), with several etoposide concentrations for different time points 
(Figure 3-2). In both assays only a slight increase of the parameter % DNA in 
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tail was detected. This result suggested that neutral comet assays were not 
suitable to detect etoposide-induced DNA damage. Alkaline comet assays 
were then carried out using RC92a/hTERT cells and two primary samples 
(Y004/09 and Y025/09), (Figure 3-3). In RC92a/hTERT cells the levels of 
DNA damage increased strikingly and revealed more than 90% DNA in tail 
for all treated samples (Figure 3-3 A). In primary samples the response 
appeared to be weaker than in RC92a/hTERT cells, but still stronger than 
with neutral comet assays (Figure 3-3 B and C). Comparative images 
presenting the observed amounts of DNA damage, revealed by either neutral 
or alkaline comet assays, emphasize the suitability of the alkaline comet 
assay to detect DNA damage in our system (Figure 3- 4). We concluded that 
the high pH in the alkaline version encouraged the unwinding and release of 
DNA better than in neutral comet assays and was furthermore able to detect 
several types of DNA damage induced by etoposide. 
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Figure 3-1 Assessment of DNA damage using comet assays. Cells were subjected to 
gel electrophoresis and stained with SYBR Gold for subsequent visualization by 
immunofluorescence microscopy. (A) The “head” of a comet represents undamaged 
DNA, whereas the “tail” represents damaged DNA. Image shows measurements 
made by AutoComet TriTek software. (B) Examples for cells with and without DNA 
damage from an alkaline comet assay. (C) Images as shown in B were analysed by 
TriTek comet score software. 
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Figure 3-2 Determination of suitability of neutral comet assays to detect etoposide-
induced DNA damage. (A) PNT1A cells and (B) selected primary cells (H020/09) were 
treated with the indicated concentrations and time points with etoposide and % of 
DNA in tail was quantified by neutral comet assays. Bars represent median values of 
% DNA in tail. At least 50 cells were analyzed, but usually more than 100 depending 
on their availability. 
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Figure 3-3 Determination of suitability of alkaline comet assays to detect 
etoposide-induced DNA damage. (A) RC92a/hTERT cells and (B, C) primary cells 
(Y004/09 and Y025/09 respectively) were treated with different concentrations of 
etoposide for the indicated times and % DNA in tail was assessed by alkaline comet 
assays. Bars represent median values of % DNA in tail. At least 50 cells were 
analyzed, but usually more than 100 depending on their availability. 
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Figure 3-4 Alkaline comet assays are more suitable for detecting etoposide-induced 
DNA damage. The images are representative for the highest amounts of % DNA in 
tail observed in prostate primary cells by performing (A) a neutral comet assay and  
(B) an alkaline comet assay. 
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3.1.1.2 Comparative study of the levels of DNA damage using alkaline 
comet assays 
In view of these findings we decided to proceed with alkaline comet assays 
for a comparative study of the DNA damage response in selected primary 
prostate malignant and benign populations. Initially, a number of alkaline 
comet assays with different etoposide concentrations and time points was 
conducted (Figure 3-5). With this assay SCs showed lower levels of DNA 
damage. There were significant differences between SCs vs. TAs (p = 
<0.001) and SC vs. CB (p= 0.007) at 30 µM etoposide for 45 min. When 
using more aggressive treatment conditions we observed a similar trend. 
Both malignant and benign SCs acquired less DNA damage than TAs and 
CBs. At an etoposide concentration of 250 µM for 45 min we found a 
significant difference in DNA damage between SCs and TAs (p=0.0029).  
During the preparation of the previously described assays we found that the 
combination of 30 µM etoposide for 45 min was the most suitable. It was 
therefore applied to a higher number of samples (as already included in 
Figure 3-5). Treatment, which was too aggressive, might have resulted in (i) 
missing a potentially different response among the populations and (ii) 
creating an enormous DNA fragmentation below the detectable range of a 
comet assay. The % DNA in tail seemed to be reduced at aggressive 
treatment conditions relative to lower concentrations (Figure 3-5). This 
might have been due the obliteration of the DNA, which would make it 
undetectable. We analyzed the comet assays performed for our optimal 
treatment condition in more detail by separating malignant and benign 
samples and by enabling a correlation of SCs, TAs and CBs that originated 
from the same patient (Figure 3-6). When we compared the extent of DNA 
damage in malignant SCs to their corresponding TAs, we found a higher 
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susceptibility to etoposide in TAs (p= 0.008), (Figure 3-6 A). CBs from the 
same tissue were also seen to present with a higher amount of DNA damage 
than SCs, but in this case the difference was not significant. Interestingly, 
the amounts of DNA damage measured in malignant SCs were very low 
(median fold change of % of DNA in tail = 1.3), but an increased damage 
response was seen in SCs from the samples H018/11 and H090/09, which 
were both taken from patients that underwent hormone therapy. In selected 
populations of benign origin, we found a significant increase of % of DNA in 
tail in TAs after etoposide exposure when comparing them to SCs (p=0.008) 
(Figure 3-6 B). Benign CBs increased their levels of DNA damage post 
treatment, but we found no significant difference in comparison to SCs and 
TAs. 
To visualize these differences between selected populations before and after 
treatment in regard to the % of DNA in tail, comparative example images 
were taken (Figure 3-7). As graphed in Figure 3- 6, SCs displayed less DNA 
damage following treatment (Figure 3-7 A, B) than TAs (Figure 3- 7 C, D) 
and CBs (Figure 3-7 E, F). 
In conclusion, both malignant and benign prostate SCs were less sensitive to 
etoposide treatment than their differentiated counterparts. Their decreased 
susceptibility to the induction of DNA damage might therefore be correlated 
with a higher resistance to conventional treatments. A method to examine 
the DNA damage response further and even more detailed than with comet 
assays (direct measurement), is the use of the DNA damage marker γH2A.X, 
the phosphorylated form of a  protein that is indicative of DNA lesions 
(indirect measurement).    
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Figure 3-5 Prostate SCs from benign and malignant samples are more resistant to 
etoposide treatment than CBs and TAs. Malignant and benign SCs, TAs and CBs 
were selected from cultures grown from primary tissues. Cells were treated for the 
indicated time points in suspension and the % of DNA in tail was quantified by 
alkaline comet assays. Each symbol represents one patient. Black marks represent 
median values of % DNA in tail. At least 50 cells, but usually more than 100 were 
analyzed for the treatment condition 30 µM, 45 min depending on their availability. 
For the other treatment conditions occasionally less than 50 cells were available for 
analysis. These exceptions are listed in the appendix. Wilcoxon rank sum test for 
the 45 min, 30 µM: SC vs. CB: p= 0.007, SC vs. TA: p = <0.001; 45 min, 250 µM SC 
vs. TA: p = 0.0029. Non-significant p-values are listed in the appendix. 
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Figure 3-6 Primary malignant and benign SCs are more resistant to etoposide 
treatment than CBs and TAs. (A) Malignant and (B) benign SCs, TAs and CBs were 
selected from cultures grown from primary tissues. Cells were treated with 30 µM 
etoposide for 45 min in suspension and the % of DNA in tail was quantified by 
alkaline comet assays. Each symbol represents one patient. At least 50 cells were 
analyzed, but usually more than 100 depending on their availability. Wilcoxon rank 
sum test for malignant samples: SC vs. TA: p= 0.008; Wilcoxon rank sum test for 
benign samples: SC vs. TA: p= 0.008. Non- significant p-values are listed in the 
appendix. 
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Figure 3-7 Comparative images of primary prostate populations following etoposide 
treatment. (A) SCs, (B) TAs and (C) CBs were selected from primary cultures and 
treated with 30 µM etoposide for 45 min. DNA damage was quantified by alkaline 
comet assays. Note the increasing % DNA in tail in (B) and (C) between the images 
on the left (before treatment) and images on the right (after treatment). The SCs 
could only be plated in a lower density, as SC yields are very low.  
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3.1.2 Assessment of the DNA damage after etoposide treatment by 
γH2A.X  
3.1.2.1 Suitability of the DSB marker γH2A.X to assess DNA damage 
and repair  
In order to detect DSBs in malignant and benign primary prostate SCs and 
TAs after exposure to etoposide, cells were stained for the DSB marker 
γH2A.X. The γH2A.X staining protocol was initially tested on unselected 
LNCaP, BPH-1 and primary cells (Figure 3-8). In both LNCaP and primary 
cells the number of γH2A.X positive cells increased strongly after treatment 
at different concentrations (Figure 3-8 A and E), whereas BPH-1 cells 
showed a weaker response (Figure 3-8 C). To assess whether or not γH2A.X 
was a suitable marker to examine repair in primary prostate cells, the drug 
was replaced by normal media after 45 min and cells were kept at 37ºC for a 
further 24 h. In LNCaP and primary cells the γH2A.X foci were reduced ~50% 
in comparison to the levels observed directly after 30 min (Figure 3-8 B, F). 
In BPH-1 cells a slight repair was observed after 24 h when compared to the 
initial levels of γH2A.X at 30 min. (Figure 3-8 D). 
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Figure 3-8 Determination of suitability of γH2A.X staining to assess etoposide 
induced DNA damage in cell lines and primary cells. (A, B) Unselected LNCaP cells, 
(C, D) unselected BPH-1 cells and (E, F) unselected primary cells (Y023/09) were 
plated on collagen I-coated 8-well chamber slides. (A, C, E) Cells were treated with 
the indicated concentrations of etoposide for 30 min, fixed, permeabilized and 
stained with a γH2A.X antibody. (B, D, F) The drug-containing media was replaced 
by normal media after 45 min and cells were kept for 24 h at 37ºC to assess repair. 
The value for the concentration 125 µM in (B) is not applicable, likely due to a 
mistake during the preparation. At least 50 cells, but usually more than 100 were 
counted by immunofluorescence microscopy depending on their availability and the 
percentage of γH2A.X positive cells was determined. 
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3.1.2.2 Qualitative differences of γH2A.X positive cells in primary cells 
When examining γH2A.X up-regulation in malignant and benign primary 
cells by immunofluorescence microscopy, qualitative differences regarding 
the γH2A.X pattern were observed. Mainly, γH2A.X positive cells with 
“classical” punctate foci and others with a diffuse staining throughout the 
nucleus (pan-nuclear staining). These two different types were further 
divided resulting in five different phenotypes (Figure 3-9 and 3-10):   
 Punctate foci were divided into the types “5-10 foci” and “>10 foci” 
  The pan-nuclear γH2A.X distribution came with different intensities 
and was therefore divided into: “pan-nuclear light” (PL), “pan-nuclear 
intermediate” (PI) and “pan-nuclear strong” (PS).  
This classification served later for a more detailed investigation of selected 
primary cells. 
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Figure 3-9 Schematic presentation of different γH2A.X phenotypes identified by 
immunofluorescence microscopy. Five different phenotypes of γH2A.X positive 
nuclei were found in malignant and benign primary prostate cells.  
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Figure 3-10 Different γH2A.X phenotypes in primary prostate cells identified by 
immunofluorescence microscopy. Primary prostate cells were plated on collagen I–
coated 8-well chamber slides, fixed and permeabilized. Cells were stained with an 
antibody against γH2A.X (A, B, C, D; images on the left) and with DAPI (A, B, C, D; 
images on the right). Note that the PL signal appears significantly more intense 
through the eyepiece and intensity decreases when images are transferred for 
printing. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                         RESULTS 
 
105 
 
3.1.2.3 Quantification of γH2A.X positive cells in selected primary 
malignant and benign populations following etoposide treatment 
Selected malignant and benign primary cells were incubated with etoposide 
for 45 min and stained for γH2A.X (Figure 3-11 and 3-12). The percentage 
of γH2A.X positive cells increased after treatment, which is presented as a 
fold change (Figure 3-11 A and 3-12 A). However, when comparing the 
median DNA damage levels of the two groups malignant SCs sustained 
significantly less damage in comparison to their corresponding TAs (p= 
0.032), (Figure 3-11 A). When applying etoposide to SCs and TAs of benign 
origin, an increased γH2A.X expression was found in both populations. 
Benign-derived SCs also sustained less DNA damage than TAs, even though 
the difference was not statistically significant (Figure 3-12 A).  
A second set of selected malignant and benign cells was subjected to 
etoposide for 45 min, replenished with normal media and left for 24 h at 
37ºC to allow repair (Figure 3-11 B and 3-12 B). In benign SCs and TAs a 
significant repair was observed when compared to the initial γH2A.X levels 
at 45 min (SCs 45 min vs. SCs 24 h: p=0.047; TAs 45 min vs. TAs 24 h: 
p=0.047; compare Figure 3-12 A to 3-12 B). However, it is difficult to 
compare the repair efficiencies of the two populations, as they sustained 
different amounts of DNA damage at 45 min. For SCs and TAs from 
malignant tissues no significant differences were revealed. In this case this 
is very likely due to the low number of malignant samples available for the 
statistical analysis (n=3). The assessments performed for Figures 3-11 and 
3-12 take all of the five different types of γH2A.X phenotypes into account.  
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Figure 3-11 SCs from malignant tissues are more resistant to etoposide treatment 
than their corresponding TAs. (A) SCs and TAs were selected from cultures grown 
from malignant primary tissues and plated on collagen I-coated 8-well chamber 
slides. Cells were treated with 30 µM etoposide for 45 min, fixed, permeabilized 
and stained for γH2A.X. (B) The drug-containing media was removed after 45 min, 
replaced by normal media and cells were kept for 24 h at 37ºC to allow repair. The 
evaluation includes all different types of yH2A.X positive cells as explained in 
Figures 3-9 and 3-10. Each symbol represents one patient. At least 50 cells, but 
usually more than 100 were counted by immunofluorescence microscopy depending 
on their availability and the percentage of γH2A.X positive cells was determined. 
Wilcoxon rank sum test: TA vs. SC 45 min: p= 0.032. Non-significant p-values are 
listed in the appendix. 
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Figure 3-12 SCs from benign tissues are more resistant to etoposide treatment than 
their corresponding TAs. (A) SCs and TAs were selected from cultures grown from 
benign primary tissues and plated on collagen I-coated 8-well chamber slides. Cells 
were treated with 30 µM etoposide for 45 min, fixed, permeabilized and stained for 
γH2A.X. (B) The drug-containing media was removed after 45 min, replaced by 
normal media and cells were kept for 24 h at 37ºC to allow repair. The evaluation 
includes all different types of yH2A.X positive cells as explained in Figures 3-9 and 
3-10. Each symbol represents one patient. At least 50 cells, but usually more than 
100 were counted by immunofluorescence microscopy depending on their 
availability and the percentage of γH2A.X positive cells was determined. The non-
significant p-values are listed in the appendix. 
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3.1.2.4 Qualitative differences of γH2A.X in selected primary 
populations following etoposide treatment 
To assess the frequency of the different γH2A.X phenotypes (as summarized 
in Figures 3-11 and 3-12), the patterns 5-10 foci, >10 foci, PL, PI and PS 
were quantified for each selected population (Figure 3-13). The different 
types of yH2A.X patterns were seen to increase after 45 min of treatment in 
all malignant populations (Figure 3-13 A), with SCs being affected less than 
TAs. The types >10 foci and PL were found to be particularly up-regulated 
when comparing malignant SCs to TAs. The phenotype >10 foci was 
significantly elevated in TAs when compared to SCs (p=0.032).  After 24 h 
the number of γH2A.X positive cells dropped for most phenotypes in SCs 
and TAs, but increased for PL and PI in the TA population (Figure 3-13 B).  
In benign samples the different yH2A.X phenotypes were found mostly at 
similar levels for TA and SCs, but the phenotype >10 foci was more strongly 
expressed in TAs (Figure 3-13 C). After 24 h, several γH2A.X phenotypes 
were present in comparable quantities in both benign SCs and TAs, but SCs 
had a higher fold–change of >5-10 foci and TAs in PI.  
In conclusion, malignant and benign SCs and TAs both responded to 
etoposide exposure by increased DNA damage, with SCs being less 
susceptible than TAs. 24 h of repair diminished mostly the higher DNA 
damage in benign and malignant TAs, except for the patterns PL and PI in 
malignant TAs. Less is known about the meaning of different γH2A.X 
phenotypes, but the lower γH2A.X levels found in SCs after an initial dose of 
etoposide might be correlated with their resistance phenotype. 
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Figure 3-13 Quantification of the different γH2A.X patterns in SCs and TAs from 
malignant and benign primary samples. (A, C) Primary cells from malignant and 
benign samples were selected and plated on collagen I-coated 8-well chamber 
slides. Cells were treated with 30 µM etoposide for 45 min, fixed, permeabilized 
and stained for γH2A.X. (B, D) The drug-containing media was replaced by normal 
media after 45 min and cells were left for 24 h at 37ºC to allow repair. At least 50 
cells, but usually more than 100 were counted by immunofluorescence microscopy 
depending on their availability and the percentage of the different phenotypes of 
γH2A.X positive cells was determined. Bars represent median values of fold change 
of the different patient groups as shown in Figures 3-11 and 3-12. Wilcoxon rank 
sum test for cancer 45 min >10 foci SC vs. TA: p= 0.032. Non-significant p-values 
and the determination of the median fold changes are listed in the appendix. 
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3.1.2.5 Detection of γH2A.X after excess thymidine treatment 
The DNA damage marker γH2A.X has been shown to respond to DSBs, but 
also to SSBs [166, 276, 277]. To assess whether this is the case in prostate 
primary cells we assessed γH2A.X expression in selected populations after 
72 h treatment with excess thymidine. Excess thymidine is a trigger of 
replications stress that results in the formation of SSBs, but not DSBs. The 
cells increased γH2A.X expression which indicated that γH2A.X responds to 
SSBs in prostate primary cells (Figure 3-14). 
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Figure 3-14 γH2A.X detects SSBs in primary prostate cells. Benign SCs, TAs and CBs 
were isolated from primary cultures, plated on collagen I-coated 8-well chamber 
slides and incubated for 72 h with 2 mM thymidine. Cells were fixed, permeabilized 
and stained for γH2A.X. At least 50 cells, but usually more than 100 were counted 
by immunofluorescence microscopy depending on their availability and the 
percentage of the different types of γH2A.X positive cells was determined. 
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3.2 Clonogenic recovery assays to determine the susceptibility of 
prostate epithelial cell populations to etoposide treatment 
3.2.1 Optimization of the experimental set up for clonogenic 
recovery assays 
Clonogenic recovery assays are an important method to investigate the drug 
resistance potential of cells. We seeded SCs and TAs originating from 
malignant and benign prostate tissues and assessed the influence of 
etoposide on their colony forming efficiency, which is defined as number of 
colonies/cells plated÷100. Reduction of colony forming efficiency by 
etoposide treatment indicates susceptibility to the drug. Colonies were 
classified into 2+, 4+, 8+, 16+ and 32+ cells, which equals 1, 2, 3, 4 and 5 
population doublings, respectively. Example images for a clonogenic assay 
performed with primary prostate cells are shown in Figure 3-15. First, 
unselected primary cells were plated and treated with DMSO (vehicle) or 30 
µM or 250 µM etoposide for 45 min and 3 h (Figure 3-16 A). Only at the 
combination 30 µM for 45 min did the cells form colonies, whereas all other 
combinations were found to be too aggressive and prevented the cells from 
any colony formation (0% colonies), (Figure 3-16 A). Hence, we decided to 
proceed with the concentration 30 µM etoposide for 45 min, as (i) we were 
able to find colonies at this concentration and (ii) the treatment conditions 
matched the treatment conditions used in the γH2A.X and comet assays, 
which enabled a better correlation of the results revealed from these 
different assays. To determine the appropriate time points for analyzing the 
number of colonies, the first two clonogenic recovery assays on selected 
populations were assessed at different time points (Figure 3-16 B and C). At 
day 4 (Figure 3-16 B) and day 3 (Figure 3-16 C) only a low number of 
colonies grew in the DMSO treated cells and the biggest colony size 32+ 
was only present in moderate quantities (as seen in 3-16 B). However, after 
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8 days (Figure 3-16 B) and 6 days (Figure 3-16 C) we found an increased 
colony number and increased colony sizes in SCs and TAs from both 
samples. Based on this assessment we decided that clonogenic recovery 
assays should be grown at least for one week prior to their assessment. 
However, the optimal time frame for growing a clonogenic recovery assay 
was later found to be strongly patient specific and in some cases longer 
times (up to 16 days) were required. 
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Figure 3-15 Examples for colonies observed in clonogenic recovery assays. (A) A 
crystal violet stained 32+ colony. (B) Crystal violet stained cells of a clonogenic 
recovery assay treated with DMSO (upper panel) or etoposide (lower panel). 
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Figure 3-16 Suitability of clonogenic recovery assay to assess susceptibility of 
primary prostate cells to etoposide treatment. (A) Unselected benign primary cells 
(Y030/11) were seeded as triplicates on collagen I-coated 6-well plates with 
irradiated feeder cells. Cells were treated with etoposide for the indicated times and 
concentrations or with the appropriate dilution of DMSO and kept at 37ºC. After one 
week different colony sizes (2+, 4+, 8+, 16+, 32+) were assessed. (B, C) Malignant 
primary cells (H035/11, PE531) were selected and seeded as triplicates on collagen 
I-coated 6-well plates with irradiated feeder cells. Cells were treated with 30 µM 
etoposide for 45 min or the appropriate dilution of DMSO and kept at 37ºC. The 
different colony sizes (2+, 4+, 8+, 16+, 32+) were assessed after the indicated 
days. The colony forming efficiency was calculated by the formula number of 
colonies/cells plated÷100. Note that the error bars refer to the total number of 
colonies observed. Error bars for specific colony sizes are listed in the appendix. 
 
 
                                                                                                         RESULTS 
 
118 
 
 
 
                                                                                                         RESULTS 
 
119 
 
3.2.2 Comparison of the clonogenic recovery in SCs and TAs 
A series of clonogenic recovery assays were conducted with SCs and TAs 
from malignant (n=7, Y062/11 = CRPC) and benign origin (n=2) to compare 
their therapy resistance potential (Figure 3-17 A and B). In the majority of 
cancer samples SCs showed a higher clonogenic recovery (except for 
H049/11). We found that benign samples usually failed to form any colonies 
(also when not treated with etoposide) and only Y031/11 and Y030/11 
produced colonies. TAs from the sample Y031/11 showed a higher 
clonogenic recovery, whereas for Y030/11 SCs were more resistant. The 
bars as shown in Figure 3-17 A represent the entire five colony sizes 
observed in summary. A detailed analysis of the colony sizes is shown in 
Figure 3-17 B. The colony sizes 8+ and 16+ were found frequently and we 
assume that these would have developed into 32+ colonies, if allowed more 
time to continue. However, not all colonies grew with the same pace and 
faster growing ones would have started to merge and overgrow the plate. 
For this reason the clonogenic recovery assays had to be evaluated usually 
after 1-2 weeks. Please note that the risk of colonies merging can’t be 
excluded for the samples YO30/11 and YO31/11 due to an enhanced 
growth in the DMSO control wells. In one case SCs and TAs from a malignant 
sample (H035/11) were treated with 30 µM and left for 3 h (Figure 3-17 C). 
TAs did not form any colonies under this condition, but a small number of 
SCs survived and formed colonies in the sizes 32+ and 16+. In conclusion, 
the clonogenic recovery assays revealed that in particular malignant SCs 
recovered better from etoposide treatment than malignant TAs, which might 
be another hint for their role in therapy resistance in prostate cancer. 
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Figure 3-17 Malignant SCs have a higher clonogenic recovery after etoposide 
treatment than TAs. Malignant and benign primary cells were selected and seeded 
as triplicates on collagen I-coated 6-well plates with irradiated feeder cells. Cells 
were treated with 30 µM etoposide for 45 min or the appropriate dilution of DMSO 
and kept at 37ºC. (A) Summary of all colony sizes observed. (B) Detailed 
presentation of different colony sizes (2+, 4+, 8+, 16+, 32+) as shown in (A). (C) 
Selected cells of H035/11 were treated with 30 µM etoposide for 3 h. The 
percentage of the colonies grown was calculated by the formula number of 
colonies/cells plated÷100.  Note that the error bars refer to the total number of 
colonies observed. Error bars for each specific colony size are listed in the 
appendix. 
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3.3 Examination of the cell cycle status in primary prostate cells 
using Ki67 
Since the cell cycle status plays a critical role in mediating therapy-
resistance, selected primary cells originating from malignant and benign 
samples were selected and assessed for Ki67 expression. Ki67 is a nuclear 
protein strictly associated with proliferating cells [278]. It is present in all 
active stages of the cell cycle (G1, S, G2, and mitosis), but is absent from 
quiescent cells (G0) [278]. We investigated the presence of Ki67 by 
immunofluorescence microscopy (Figure 3-18 A and B). A significantly lower 
percentage of SCs from malignant tissues was found to be cycling (Ki67 
positive) in comparison to malignant TAs (p=0.016) and CBs (p=0.008) 
(Figure 3-19 A). The assessment of selected benign samples revealed a 
similar trend (Figure 3-19 B). Benign SCs proliferated less in comparison to 
benign TAs and CBs. These data suggest that the cell cycle might play a role 
in the therapy-resistance of SCs derived from malignant prostate tissues. 
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Figure 3-18 Example images for Ki67 staining in primary cells. Primary prostate 
cells were seeded on collagen I-coated 6-well plates, fixed, permeabilzed and 
stained for Ki67 and assessed by immunofluorescence microscopy. (A) Cells positive 
for Ki67 (left) and corresponding DAPI (right). (B) Cells negative for Ki67 (left) and 
corresponding DAPI (right). 
 
 
 
 
                                                                                                         RESULTS 
 
124 
 
 
                                                                                                         RESULTS 
 
125 
 
Figure 3-19 A lower percentage of SCs of malignant and benign primary prostate 
samples is in cell cycle in comparison to TAs and CBs. (A) Primary malignant and (B) 
benign prostate cells were selected and plated on collagen I-coated 8-well chamber 
slides. Cells were fixed and stained with an antibody against Ki67. At least 50 cells, 
but usually more than 100 were counted by immunofluorescence microscopy 
depending on their availability and the percentage of Ki67 positive cells was 
determined. One exception was made for SCs derived from cancer sample H048/11: 
a number of 32 cells had to be analysed. Wilcoxon rank sum test cancer samples SC 
vs. TA: p= 0.016; SC vs. CB: p= 0.008. Non-significant p-values are listed in the 
appendix. 
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3.4 Assessment of cell death in primary cells  
One of the main obstacles in cancer therapy is resistance to apoptosis. In 
respect to prostate cancer cells our previous findings revealed that primary 
prostate cells reduced their colony forming efficiency through etoposide 
treatment (even if in TAs this effect was stronger than in SCs). This 
observation might have been a consequence of cell death through 
apoptosis. Alternatively, the cells could have remained viable, but suffered a 
loss of their colony forming potential. To address these questions further, 
we applied MTS assays to assess cell viability and apoptotic assays with an 
activated caspase in situ marker. Additionally, autophagy was tested as an 
alternative treatment response. 
3.4.1 Viability assays to assess the effect of anti-cancer drugs on 
unselected primary cells 
MTS assays on unselected primary prostate cells (PE665) served to elucidate 
the cell viability (Figure 3-20 A-F). The viability of cells decreased after 72 h 
incubation with the anti-cancer drugs etoposide (B), docetaxel (C), 
carboplatin (D), camptothecin (E) and doxorubicin (F).    
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Figure 3-20 Unselected malignant primary cells reduce viability after treatment with 
anti-cancer drugs. Unselected malignant primary cells (PE665) were plated on 
collagen I-coated 96-well plates, incubated with different concentrations of 
etoposide, docetaxel, carboplatin, camptothecin and doxorubicin and left for 72 h 
at 37ºC. Viability was assessed using MTS. Concentrations are shown from high to 
low (left to right) in each graph and listed in numbers in the appendix. The 
percentage of viable cells was determined by setting the DMSO control (first bar of 
each graph, grey) to 100% and calculating the values for the treated wells in 
percentile relation to that. Exception: The grey bar in the DMSO chart (upper panel, 
left) represents an untreated control. 
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3.4.2 Detection of active caspases for assessment of apoptosis  
The previously described observations in clonogenic recovery assays and 
MTS assays raised the question of whether cells underwent apoptosis 
following treatment. For this reason we applied an activated caspase in situ 
marker for flow cytometry analysis to examine the apoptotic response to 
etoposide treatment using the described gating strategy (Figure 3-21). 
Initially, we examined the suitability of the caspase in situ marker as an 
indicator for apoptosis in the prostate cell lines RC165N/h-TERT and 
RC92a/h-TERT (Figure 3-22 A-C).  The cells were incubated for 12 h, 24 h, 
48 h and 72 h with 15 µM, 30 µM, 60 µM and 125 µM etoposide. We 
detected an increase of active caspases at 48 h and 72 h in a dose 
responsive manner in both cell lines. To exclude the possibility that 
etoposide interfered with the FITC-channel (where the caspase in situ 
marker was measured), cells were incubated with 60 µM etoposide for 48 h 
and compared to an unstained and untreated population of cells. Etoposide 
did not interfere with the FITC-channel. When cells were treated with 
etoposide the activated caspase positive population increased significantly, 
suggesting an apoptotic mechanism.   
However, when the same caspase in situ marker was applied to primary 
samples, the outcome differed from that observed in cell lines (Figure 3-23). 
Cells originating from a patient who had failed hormone therapy (H149/11), 
a patient with a malignant disorder but without hormone therapy (H054/11) 
and cells from a BPH patient (Y030/11) were incubated with 125 µM 
etoposide for 24 h, 48 h and 72 h. The detected activated caspase levels for 
the three different samples were between 15 and 30% for the untreated and 
treated controls. None of the samples increased caspase activity significantly 
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at any treatment condition suggesting that apoptosis was blocked in these 
cells. 
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Figure 3-21 Gating strategy to detect apoptotic cells by flow cytometry. Debris was 
excluded by using the Forward/ Side Scatter. The cells in gate R1 were further 
analysed for binding to the caspase marker CaspACE™ FITC-VAD-FMK. The 
unstained control (cells only) was used to set the gates for the untreated and 
etoposide treated controls. Plots present the gating strategy by showing a primary 
sample (Y030/11). The same gating strategy was applied for cell lines (not shown). 
Note that there is no increase of apoptotic cells after 125 µM etoposide treatment, 
as apoptosis was found not to be activated in primary cells. 
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Figure 3-22 RC165N/ h-TERT and RC92a/ h-TERT cells undergo apoptosis after 
exposure to etoposide. (A) RC165N/ h-TERT and (B) RC92a/ h-TERT cells were 
incubated for the indicated time points and concentrations (µM) with etoposide and 
kept at 37ºC. Cells were stained with the caspase marker CaspACE™ FITC-VAD-FMK 
for flow cytometry. C demonstrates the relevant controls using the example of 
RC92a/h-TERT.  
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Figure 3-23 Unselected primary cells do not activate caspases following treatment 
with etoposide. Unselected primary cells (H149/11=CRPC; H054/11=cancer; 
Y30/11=BPH) were incubated for the indicated time points with 125 µM etoposide 
and kept at 37ºC. Cells were stained with the caspase marker CaspACE™ FITC-VAD-
FMK for flow cytometry. 
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3.5 Assessment of autophagy  
Since we found no sign for apoptotic cell death in primary prostate cells we 
assessed autophagy as an alternative response with an antibody against 
LC3B (the protein is thought to be involved in formation of autophagosomal 
vacuoles), (Figure 3-24). Primary cells were left untreated (Figure 3-24, 
upper image) or in 60 µM etoposide for 60 h (Figure 3-24, lower image). 
When assessed by confocal microscopy, treated cells were found to be LC3B 
positive, suggesting autophagy. It would have been interesting to assess 
this phenomenon further for different cell populations of different samples, 
as it might have provided information about an alternative cell death. In 
conclusion, primary prostate cells were found to lose viability, but were at 
the same time resistant to apoptosis. Preliminary results point out that the 
cells might have undergone autophagy, a mechanism that can result in cell 
survival or cell death. 
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Figure 3-24 Primary cells display features of autophagy following etoposide 
treatment. Primary cells of a cancer sample (H131/11) were plated on collagen I-
coated 8-well chamber slides  and kept in absence (A) or presence (B) of etoposide 
(60 µM, 60 h) at 37ºC. Cells were fixed and stained with an antibody against LC3B 
and assessed by confocal mircoscopy. 
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3.5 The role of ABC-transporters in mediating therapy-resistance 
in primary prostate populations 
3.5.1 Gene expression analysis of ABC-transporters in primary 
prostate cells 
ABC multidrug transporters are expressed in many human tumours and are 
thought to be a major source of chemoresistance. Hence, we studied ABC-
transporters at the mRNA level by re-assessment of a microarray analysis 
prepared for a previous project [109]. SCs and CBs from malignant and 
benign primary prostate tissues revealed the presence of several ABC-
transporters in both cell types (Figure 3-25). In particular ABCB1, ABCC1 
and ABCG2 belong to the three major types of ABC-transporters correlated 
with drug resistance and were therefore of further interest. ABCB1 was 
present in about 50% of the tested samples, although its expression at the 
mRNA level was very low. ABCG2 was equally expressed in SCs and CBs. We 
found the etoposide-transporting protein ABCC1 [279] significantly higher 
expressed in SCs when compared to CBs (p= 0.002).  ABCC5, which has not 
been shown to use etoposide as a substrate [279], was significantly higher 
expressed in CBs (p= 0.0016). According to these results, ABC-transporters 
might play a role in mediating therapy-resistance and explain some of the 
effects observed in this study. We decided therefore to proceed with 
functional assays. 
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Figure 3-25 Expression of ABC-transporters at mRNA level. Microarray data 
performed with primary malignant and benign SCs and CBs were obtained from 
Birnie et al. 2008 [109] and specifically analysed for mRNA-expression levels of 
ABC-transporters. Each line within one mark presents one patient. P-values marked 
in green indicate significant differences between the two populations: SC vs. CB for 
ABCC1 p=0.002; SC vs. CB ABCC5 p=0.0016. Non-significant p-values are shown 
in brown above the figure. Analysis by Alastair Droop. 
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3.5.2 Assessment of the functionality of ABC-transporters in primary 
cells using calcein efflux assays 
As described previously, a gene expression analysis of ABC-transporters in 
malignant and benign primary samples revealed that SCs and CBs expressed 
various ABC-transporters. However, the microarray-derived expression data 
did not necessarily reflect the cells’ capability to efflux chemotherapeutic 
drugs, as the ABC-transporters might not be expressed at protein level or 
not be functional, if expressed.  For this reason, a calcein efflux assay was 
applied to research the function of ABC-transporters in SCs, TAs and CBs.  
The method is based on the uptake of calcein-am into the cell cytoplasm 
and its metabolism into the green fluorescent substance calcein (Figure 3-
26). A decrease of calcein in the cytoplasm can then be correlated with 
functional ABC-transporters that are able to expel undesirable substances. 
Among different fluorescent substances available, calcein was considered as 
a suitable reagent for several reasons: the substance is highly fluorescent, 
which is an advantage when detecting small cell numbers. Additionally, it is 
transported by ABCC1 (calcein) and ABCB1 (calcein-am) [280]. Particularly, 
ABCC1 was of interest, as it is an etoposide-transporting resistance protein 
that was found to be significantly higher expressed in malignant and benign 
SCs. Substances that are fluorescent without prior metabolism such as 
doxorubicin, daunorubicin and mitoxantrone, were not used, as they have 
been found to lack sensitivity due to poor fluorescent properties and the 
risk of measuring a significant number of false negative results [281]. 
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Figure 3-26 Use of calcein to assess the functionality of ABC-transporters. Cells 
were incubated with calcein-am which is shortly after its uptake, metabolized into 
green fluorescent calcein. Cells that express functional ABC-transporters are able to 
efflux calcein and should therefore be less calcein positive. 
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3.5.2.1 Suitability of the plate reader to measure calcein efflux and 
rejection of other methods 
We tested different approaches to measure calcein efflux in primary prostate 
cell populations (Table 3-1). The initially chosen methods, flow cytometry 
and immunofluorescence microscopy, were rejected as they were difficult to 
conduct due to several technical disadvantages. The main difficulty with 
immuofluorescence microscopy was the inconsistent calcein signal within 
the wells where the cells were kept: the calcein signal varied strongly, 
depending on the position of the cells within the well. There were patches of 
cells that were able to metabolize the calcein-am to a greater extent than 
others. When capturing images of 100 cells per well at different time points, 
it was difficult to exclude the possibility that a change in the signal was not 
solely based on the technical variability within the wells. Furthermore, taking 
images of 3 x 100 cells (SCs, TAs and CBs) was a time-consuming 
procedure and did not allow measurement of the signal in different wells at 
exactly the same time point. The disadvantage of using flow cytometry for 
calcein efflux assessment was a constantly poor CD133 staining for SCs, 
which did not allow the collection of the required minimum of 100 cells for 
the SC population.  
In view of these disadvantages, we used a plate reader as an alternative. To 
examine  the  suitability  of  the  plate  reader  for measuring calcein, 100 to  
15 000 unselected primary prostate cells were incubated with calcein-am 
(Figure 3-27 A and B). The subsequent measurement by the plate reader 
showed that the number of seeded cells per well was proportional to the 
detected fluorescence signal.  
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Table 3-1 Advantages and disadvantages of different methods to measure calcein. 
Since the plate reader was able to detect calcein in cells and took the entire 
well into account, it was concluded to be a suitable quantitative method. To 
assess whether selected populations of primary cells were able to exclude 
calcein, SCs, TAs and CBs were seeded and the calcein signal was measured 
directly after incubation with calcein-am (15 min) and after 1 h, 2 h and 3 h 
(Figure 3-27 C and D). The initial signal measured (15 min) was between 30 
000 and 45 000 units for the three different cell populations. After 1 h the 
signal was significantly reduced to 15 000 to 25 000 units, resulting in the 
(subsequently discovered to be misleading) conclusion that all of the three 
cell types were highly capable of calcein extrusion. At 2 h and 3 h the signal 
was reduced further. This initial experiment led to the decision to conduct 
further calcein efflux assays with the same method. However, it was 
subsequently observed that the decrease of the signal and in particular the 
change between 15 min and 1 h, was highly affected by an artefact resulting 
from the required washing steps: measuring between different time points 
required washing steps in between, to exclude the possibility of measuring 
calcein in the media instead of calcein inside the cells. Unexpectedly, the 
washing steps led to a loss of cells, even though the washing steps were 
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gently performed with PBS. This was unexpected as the cells have a high 
affinity for collagen I-coated plates and are therefore strongly adherent. 
However, the loss of cells during different washing steps significantly 
influenced the measured signal, to the extent that a decrease of the signal 
due to efflux or a loss of cells through the washing, were indistinguishable.  
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Figure 3-27 Suitability of plate reader to measure calcein in primary cells. (A) The 
indicated numbers of unselected primary cells were plated in triplicate on collagen 
I-coated 96-well plates and left o/n to adhere. Cells were incubated with calcein–
am for 15 min and washed with PBS. Wells were filled with KSFM and the calcein was 
measured by a plate reader. Each bar represents the average of one triplicate. (B) 
Calcein signal of unselected cells detected by immunofluorescence microscopy. (C) 
Schematic presentation of the method used in D. (D) Primary cells (H054/11) were 
selected. CBs and TAs were seeded in 1 x triplicate on collagen I-coated 96-well 
plates. The entire SC yield was plated at one well. The selected populations were left 
for 2 h to adhere and cells were incubated for 15 min with calcein-am-containing 
media. The calcein signal was measured in the same well(s) directly (15 min) and 
after 1 h, 2 h and 3 h. Each time point represents the calcein signal for one cell 
population at the indicated times. Standard deviations for each mark are listed in 
the appendix.  
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3.5.2.2 Determination of cell loss due to different washing methods 
There were two main ways to use calcein. In Figure 3-27 C and D calcein 
was used to measure efflux. However, due to the previously described 
difficulties calcein was used in a second way: to determine the loss of cells 
on collagen I-coated 96-well plates due to required washing steps. In 
comparison the two methods used with calcein were: 
 Method 1: Use calcein to measure efflux  
          Plate cells → add calcein → wash → measure 
 Method 2: Use calcein to determine effect of washes on cell loss     
Plate cells → wash → add calcein → measure 
Figure 3-28 refers to method 2 and a detailed schematic presentation of the 
experimental set up is shown in Figure 3-28 A. Unselected populations were 
plated on collagen I -coated 96-well plates and left to adhere for 2 h (Figure 
3-28 B and C) or o/n (Figure 3-28 D and E).  Cells were washed using a 
vacuum pump (B, D) or alternatively with a pipette (C, E). The different 
washes (wash 1, wash 2, wash 3, wash 4) equal the number of washes in a 
calcein efflux experiment: wash 1 equals the washes at the 15 min point, 
wash 2 the 1 h time point, wash 3 the 2 h time point and wash 4 the 3 h 
time point. Regardless of the type of method applied for washing (vacuum 
pump or pipette) or the allowed time for adherence (2 h or o/n), the calcein 
signal decreased with increasing washes. These findings suggested that the 
washes resulted in a loss of cells leading to an artefact (as shown in Figure 
3-27 D). It was therefore not possible to distinguish between a decrease of 
the signal due to calcein efflux or due to reduction of cells on the plates due 
to washing.  
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Figure 3-28 Impact of different washing methods on the cell number in the 
collagen-coated 96-well plates. (A) Schematic presentation of the method used in 
B-E. (B-E) Unselected primary cells (H069/11) were plated as triplicates on 
collagen-coated 96-well plates and washed as indicated. Cells were left to adhere 
for 2 h (B, C) or o/n (D, E). Wells were washed with the same number of washes as 
used in Figure 3-27 by a vacuum pump (B, D) or with a pipette (C, E). After applying 
the washes calcein-am-containing media was added and left for 15 min to 
determine cells remaining after washing and measured by a plate reader. Wash 1 
equals the washes at the 15 min time point, wash 2 at the 1 h time point, wash 3 at 
the 2 h time point and wash 4 at the 3 h time point. Each bar represents the average 
measured for 1 triplicate. 
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3.5.2.3 Minimization and prevention of cell loss when conducting 
calcein efflux assays  
Due to the previously described results, there were two main ways to 
minimize or even prevent the loss of cells affecting the fluorescent signal 
significantly:  
(i) Firstly, a comparison of time points that had a minimum number of 
washes between them e.g. by comparing the values in Figure 3-27 C using 
the 2 h time point and the 3 h time point as there was only one washing 
cycle in between. However, to use the 15 min time point for comparison to 
any other value in the time course would not have been suitable, as the loss 
of cells after the 15 min time point was very high (see Figure 3-28 B, C). 
(ii) A method that entirely excluded the possibility of a decrease of signal 
due to a loss of cells caused by washing was the one used in Figure 3-29. In 
this approach TAs and CBs were plated in 2 x triplicates. Both triplicates 
were incubated for 15 min with calcein-am-containing media. One triplicate 
was measured directly after the end of the incubation time, the other 
triplicate was measured after 3 h. The number of washes was kept constant 
between the different sets of wells. Due to the SCs being such a very rare 
population, it was not possible to plate them as triplicates. The maximum 
number of SC replicate wells was therefore two, but only for samples that 
contained a high number of SCs. For those with a poor SC yield this method 
could not be used. Responses in selected populations of the malignant 
samples H035/11 and H131/11 were measured with the above mentioned 
method. Interestingly, in all cell populations, there was an increase of signal 
between the 15 min and the 3 h time point. This finding led to the design of 
a further experimental set up as described below. 
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Figure 3-29 The time points 15 min and 3 h are not suitable to measure calcein 
efflux in selected primary cells. (A) Schematic presentation of the method used in B. 
(B) CBs and TAs were seeded in 2 x triplicates (15 min, 3 h) on well collagen-coated 
96-well plates. The entire SC yield was divided between two wells. The selected 
populations were left o/n to adhere. Cells were incubated for 15 min with calcein-
am-containing media, with PBS and the calcein signal was measured directly (15 
min) or after 3 h to allow the detection of calcein efflux by the plate reader Each bar 
represents the average of one triplicate.  
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3.5.2.4 Determination of calcein efflux in unselected primary cells and 
RD-ES cells 
The observation of an increase of the signal in all cell populations between 
15 min and 3 h as presented in Figure 3-29 led to the design of a further 
experimental improvement. This was based on the assumption that all cell 
types might metabolize more calcein-am into calcein than effluxing calcein, 
in particular in the first 1 or 2 h when there might have still been a distinct 
amount of calcein-am left in the cytoplasm. Thus calcein had not been 
metabolized when measuring at earlier time points. Only after most of the 
calcein-am molecules in the cytoplasm were metabolized, should an efflux 
have been detectable (if it existed). For this reason, unselected populations 
of the malignant primary sample H054/11 and benign sample Y023/11 
were plated in four triplicates (Figure 3-30 A and B). After incubation with 
calcein-am, each triplicate was left for different times before measurement. 
In both samples the following trend was observed: the balance between 
production of calcein and its efflux changed after 2 h. Before this time point 
the metabolism into calcein was more dominant, so that a decrease of the 
signal could not be detected, even if it was likely that there was some efflux 
present also within the first 2 h. At 2 h most of the calcein-am in the 
cytoplasm seemed to be used up and an efflux was detected between 2 h 
and 3 h. Here, the numbers of the fluorescent signal in samples H054/11 
and Y023/11 rose from 15 min to 1 h and 2 h. After reaching this 
maximum, the signal decreased at 3 h. To confirm the suitability of the 
plate reader method to detect calcein efflux, the ABC-transporter 
expressing cell line ES-RD was used (Figure 3-30 C). Similar to primary 
cells, an increase of the signal was initially detected. After peaking at 2 h, 
the signal decreased due to calcein efflux. This trend was confirmed by 
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repeating the experiment (Figure 3-30 C, green bars).These results enabled 
a re-analysis of a data set acquired earlier. 
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Figure 3-30 Unselected populations of primary cells and RD-ES cells are able to 
efflux calcein. (A, B) Unselected primary cells (H054/11, Y023/11) were plated as  4 
x triplicates (15 min, 1 h, 2 h and 3 h) on collagen I-coated 96-well plates and left 
o/n to adhere. Cells were incubated with calcein-am for 15 min. Calcein-am-
containing media was washed off with PBS, replaced by KSFM and measured directly 
(15 min) or left to allow efflux for the indicated time points (1 h, 2 h, 3 h). (C) 
Calcein efflux of RD-ES cells. Each bar represents the average of one triplicate. The 
experimental set up is similar to that shown in 3-29 A. 
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3.5.2.5 Measurement of calcein efflux in primary cells 
The findings in Figures 3-27 to 3-30 directed a re-analysis of a set of data 
that was measured according to the strategy in Figure 3-27 C. It was 
produced earlier by using a vacuum pump for washes and allowing the cells 
to adhere for 2 h.  Hence, Figure 3-31 was created based on the following 
considerations:  
(i) The loss of cells when washing with a vacuum pump and allowing the 
cells to adhere for 2 h was relatively low, in particular when only comparing 
time points that did not have more than one wash in between them (only the 
difference between 15 min and 1 h would have been too high), (Figure 3-28 
B).  
(ii) According to Figure 3-30 A and B calcein efflux was detectable after 2 h. 
The change of the calcein signal in SCs, TAs and CBs is most likely due to 
efflux of calcein, even when taking into consideration that a slight loss of 
cells might have played a role for the decrease of the signal (Figure 3-31). 
When normalizing the signal measured at the 3 h time point to the one at 
the 2 h time point by setting the 2 h time point measured for each 
population to 100% no significant different efflux capabilities were found 
among the populations. This result suggests that enhanced drug efflux is 
not the dominant resistance mechanism in SCs from malignant and benign 
prostate tissues. 
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Figure 3-31 SCs do not display an enhanced efflux in comparison to TAs and CBs. 
The detection of calcein efflux was conducted as shown in Figure 3-27 C and D. CBs 
and TAs were seeded as 1 x triplicates on collagen-coated 96-well plates. The 
entire SC yield was plated on one well. The selected populations were left for 2 h to 
adhere and cells were incubated for 15 min with calcein-containing media. Cells 
were washed with PBS and the calcein signal was measured in the same well(s) after 
2 h and after 3 h. The fluorescence intensity measured after 2 h was set to 100% 
and the intensity at 3 h calculated in percentile relation to this value. Each symbol 
represents the calcein signal for one cell population of one patient. Standard 
deviations for each data point and the non-significant p-values are listed in the 
appendix. 
 
 
 
 
                                                                                                   DISCUSSION 
 
156 
 
 
 
 
 
 
 
Chapter IV 
DISCUSSION 
 
 
 
 
 
 
                                                                                                   DISCUSSION 
 
157 
 
4. DISCUSSION 
In summary our results indicate that SCs from malignant and benign 
prostate tissues are better protected against DNA damage than TAs and 
CBs. The colony forming efficiency was less affected in SCs after exposure to 
DNA damaging conditions. Following this observation we examined 
potential mechanisms of the increased therapy-resistance and investigated 
ABC-transporters, cellular quiescence, apoptotic susceptibility and 
autophagy in prostate primary cells. We found that ABC-transporters were 
expressed at mRNA level in SCs and CBs, but these seemed not to be 
causative for the enhanced therapy-resistance in SCs. However, the 
assessment of cellular quiescence, a frequent obstacle in cancer therapy, 
revealed that a higher proportion of SCs was in a dormant stage. This might 
be one of the key factors leading to an increased resistance. Unlike prostate 
cell lines, primary prostate epithelial cells seemed to lack the ability to 
undergo apoptosis after exposure to etoposide. Preliminary data suggest 
that autophagy might be an escape mechanism to apoptosis. 
4.1 Assessment of DNA damage in prostate cell populations 
following etoposide treatment 
When we employed both comet assays and staining for γH2A.X expression 
to assess DNA damage in SCs and differentiated cells from malignant and 
benign prostate tissues, by both methods the SCs were less susceptible to 
etoposide-induced DNA damage than their differentiated counterparts.  
4.1.1 Comparison of neutral and alkaline comet assays as methods to 
detect DNA damage in primary cells  
Neutral comet assays did not detect high levels of DNA damage, whereas 
alkaline comet assays were suitable for this purpose. This finding concurs 
with results from other groups that used alkaline comet assays as the 
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preferred version to detect DNA damage following etoposide treatment. For 
example Watters et al 2009, used alkaline comet assays as the method of 
choice after treating immortalized wild-type mouse embryonic fibroblasts 
with etoposide [143]. In another study neutral constant field gel 
electrophoresis (CFGE) did not detect a high amount of etoposide induced 
DNA damage in SV40 transformed fibroblasts, but alkaline CFGEs were a 
suitable technique [166]. By combining these methods the authors found 
that in their system, only 3% of the DNA strand breaks caused by etoposide 
were indeed DSBs. This observation is the most likely explanation why in 
neutral comet assays with primary cells only a moderate % of DNA in tail was 
identified in these studies.   
4.1.2 Observation of different γH2A.X phenotypes  
The previously described comet assays provide a direct measurement of 
DNA damage. In contrast, the identification of DNA damage by the histone 
variant γH2A.X is an indirect and more sensitive method. In addition to 
classical discernible γH2A.X foci, we also found cells with a pan-nuclear 
distribution of the marker. This finding is also in accordance with a previous 
study in our lab that assessed prostate primary cells for up-regulation of 
γH2A.X after irradiation. In this case, a pan-nuclear γH2A.X staining was 
found occasionally, but as this study used a different source of DNA 
damage, the predominant type of foci observed were classical foci (personal 
communication with F.M. Frame). A pan-nuclear γH2A.X pattern after 
etoposide treatment has also been identified by other groups. For example, 
in RKO cells (colon cancer) the same pattern was found after exposure to 
etoposide [275]. The authors interpreted their finding as a question of drug 
concentration and software adjustment. A pan-nuclear γH2A.X pattern after 
etoposide treatment has also been reported after treatment of mouse 
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embryonic fibroblasts [143]. Further sources of damage such as UV 
irradiation are also known to cause a pan-nuclear γH2A.X distribution [282, 
283]. Its meaning is mostly unknown, but some studies correlated the 
appearance with S-Phase cells [276, 284]. If this holds true, a higher 
percentage of malignant prostate primary TAs would be in the S-Phase, 
which agrees with the nature of TAs and is furthermore supported by our 
Ki67 staining, where a significantly higher number of TAs were in cycle. 
Presumably the unwound and open DNA during S-Phase is a cause for the 
pan-nuclear yH2A.X pattern. 
4.1.3 Higher resistance to etoposide-induced DNA damage in SCs  
The higher resistance to etoposide-induced DNA damage in SCs is in 
accordance with data from other studies and can be interpreted as a first 
hint of more successful survival for SCs. Pedriatic brain tumour 
neurospheres, which are enriched for CD133+Sox2+ CSCs, displayed a higher 
resistance to etoposide in comparison to monolayers, as shown by alkaline 
comet assays [285]. Another study showed that Hs578T cells (breast cancer) 
could be sensitized to drugs such as etoposide and doxorubicin: After 
treatment with salinomycin, the cells showed a higher amount of DNA 
breakage as assessed by comet assays and markers of DNA damage such as 
γH2A.X and 53BP1 [286]. As salinomycin has been shown to specifically 
inhibit CSCs [287], it would have been interesting to test this drug on 
prostate SCs. However, when human embryonic and induced pluripotent 
stem cells were exposed to etoposide to test their genomic stability, an 
inverse finding was revealed [288]. The pluripotent cells were more 
susceptible to DNA damage, in comparison to more differentiated cells. The 
authors did not assess possible reasons for their observation, but one 
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explanation might be that the embryonic SC were not quiescent [288], as 
CSC sometimes are [289, 290].  
4.1.4 The DNA damage response in the prostate  
Our data match studies on cultured prostate tissues derived from radical 
prostatectomy specimens that were cored at the unaffected lobe [291]. In 
the basal compartment, phosphorylation of H2A.X upon irradiation, 
etoposide or daunomycin treatment was fast, transient and dependent on 
ATM, but these responses were only moderate in luminal cells [291]. The 
authors correlated these differential DNA damage responses with distinct 
chromatin marks [291]. Basal cells contained higher levels of euchromatin, 
which is more accessible for repair complexes, whereas the DNA in luminal 
cells was packed in heterochromatin [291]. This study agrees with our 
finding in respect to the up-regulation of γH2A.X following etoposide 
treatment in TAs, which are located in the basal compartment. However, the 
previously described study did not specifically assess the prostate SCs which 
showed a differential response in our experiments. In this case, our study 
has gone deeper in understanding the DNA damage response by taking into 
account the hierarchy of the prostate epithelium and the different 
subpopulations. The higher resistance to DNA damage of primary malignant 
and benign prostate SCs in comparison to more differentiated cells has also 
been found when using irradiation (personal communication with F.M. 
Frame). Interestingly, in malignant and benign SCs the presence of 
heterochromatin was identified, which might provide an explanation for the 
lower γH2A.X levels (personal communication with F.M. Frame). 
4.1.5 Conclusions: γH2A.X up-regulation after treatment 
The up-regulation of γH2A.X after treatment is an indicator of DNA strand 
breaks, which result in different outcomes for the cell (cell cycle arrest, 
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repair or apoptosis). Whereas in the literature γH2A.X is often described as a 
specific DSB marker [166, 277] recent findings suggest that it also responds 
to different types of DNA damage such as SSBs [276]. Hence, it is likely that 
both malignant and benign prostate cells up-regulate γH2A.X not only by 
etoposide-induced DSBs, but also due to SSBs. A back-up for the 
assumption that primary prostate cells up-regulate γH2A.X due to SSBs, 
were the specific experiments, using a treatment condition that causes SSBs 
(excess thymidine): here we also observed an up-regulation of γH2A.X with 
SCs showing more resistance to DNA damage.  
A clearance of foci is correlated with repair. We monitored a reduction in the 
percentage of γH2A.X positive cells, as well as foci per cell in malignant and 
benign TAs after 24 h. In malignant and benign SCs we mainly observed a 
decrease of foci per cell. However, it was hard to compare repair in SCs and 
TAs directly, as they sustained different amounts of DNA damage and had 
therefore a different distance to the baseline. To test repair in SCs it would 
have been necessary to use a more aggressive treatment.  However, other 
groups have observed a more efficient repair e.g. in brain tumour CSCs 
[285]. 
The appearance of γH2A.X is usually seen as a sign of the genotoxic 
endpoint for the cells. Evaluating γH2A.X has been suggested as a standard 
in-vitro genotoxicity test to complement micronucleus assays, comet assays 
and mutation frequency tests [143]. According to Muslimovic et al. 10% of 
the etoposide–induced DSBs resulted in γH2A.X phosphorylation and these 
were closely related to toxicity [166]. A consequence of reaching the 
genotoxic endpoint is often apoptotic cell death e.g. after incubation with 
etoposide [292]. Our results confirm this observation in part. Indeed, for a 
high proportion of our cells, the appearance of γH2A.X foci could be 
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interpreted as a genotoxic endpoint, but we cannot confirm that this 
genotoxic endpoint results in apoptosis. The question remains as to why 
SCs acquired less DNA damage than more differentiated cells. Among many 
different reasons the stage of the cell cycle might play on important role.  
All these possibilities will be discussed. 
4.2 Clonogenic recovery of primary prostate epithelial cells 
Clonogenic assays are a meaningful tool to reveal information about the 
recovery of cells that have been exposed to various treatments. We found 
that the clonogenic potential of SCs, in particular from malignant tissues, 
was less affected following etoposide treatment than those of TAs derived 
from the same tissue. The same trend was confirmed when using irradiation 
to treat selected populations of primary prostate epithelial cells (personal 
communication with F.M. Frame). Interestingly, benign samples often failed 
to produce colonies, even when left untreated. Hence, only two clonogenic 
assays conducted with BPH derived cells were evaluated. We assume that 
this was based on the fact that cancer cells are proliferating faster and have 
therefore a higher clonogenicity than BPH cells. The two BPH samples 
capable of colony formation were those that were most Ki67 positive among 
the benign samples in our study.  
These observations of SCs of malignant origin being more resistant to drugs 
such as etoposide was also seen when using SCs from other sources and 
agrees with our data. For examples spheres grown from cultured brain 
tumour cells that were enriched for SC-like cells showed a higher clonogenic 
recovery after etoposide treatment than monolayers which only contained a 
low number of SC-like cells [285]. CD44+CD24- breast CSCs enriched cell 
lines were seen to have a higher viability after treatment with 
chemotherapeutic drugs than populations containing only a low proportion 
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of CSCs [287]. Out of 16 000 agents only salinomycin targeted the CSC 
population specifically and decreased their survival in vitro and in vivo [287]. 
Furthermore, the authors found that the common chemotherapeutic agent 
paclitaxel increased the ability of CD44+CD24- CSCs to form mammospheres 
2-fold [287]. In one case when we used a prolonged incubation time of 
etoposide (3 h instead of 45 min) the TAs were prevented entirely from 
forming colonies. The SCs were reduced in colony formation, but were still 
able to form a small number of colonies. This leads to the speculation that 
these recovering cells might be the ones that are causal for a relapse in vivo. 
Indeed, there are reports about a small fraction of tumour cells that survive 
therapy, namely minimal residual disease, not only in leukemia, but also 
lung cancer and breast cancer [293-296]. Our data suggest that minimal 
residual disease in prostate cancer might be mediated by SCs rather than 
differentiated cells. The hallmarks that provide the protection specifically for 
SCs from malignant tissues are very likely to be multifactoral. Examples of 
protection mechanisms of CSCs, are  cellular dormancy [297, 298], 
expression of ABC-transporters [266, 267, 280, 281, 299-305] apoptotic 
resistance [218-220, 306-309], limitation of ROS production [254] or the 
presence of high levels of heterochromatin (personal communication with 
F.M. Frame), [291], and enhanced DNA repair [297]. Some of these 
mechanisms were assessed in this study and will be discussed below.  If it 
holds true that CSCs are the main drivers of tumour recurrence, future 
strategies to target specifically CSCs are crucial. Some approaches have 
been already made e.g. high throughput screening to identify agents that 
target CSCs in vitro and in vivo [287]. However, there is an urgent need to 
study these agents more extensively on cells cultured from patient samples 
instead of cell lines. Nevertheless, there are a few clinical trials for different 
types of cancer e.g. pancreatic, breast and colon present at the time that 
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aim to target major signaling pathways in CSCs such as Wnt, Hedgehog or 
Notch [310].  
4.3 Cellular quiescence as a resistance mechanism in SCs derived 
from malignant prostate tissues 
Cellular quiescence or dormancy refers to cells in the G0 phase of the cell 
cycle. Quiescent cells are an obstacle in cancer therapy, as treatments are 
usually directed against fast proliferating cells [311]. We assessed the 
quiescence in selected populations of primary prostate epithelial cells of 
malignant and benign origin and found that a higher proportion of SCs, in 
comparison to TAs and CBs, was Ki67 negative. This finding is in accordance 
with the nature of normal tissue SC that are usually dormant and therefore 
better protected against DNA damage [297]. This enables SCs to avoid 
mutations through replication that would diminish the potential for self-
renewal and differentiation resulting in the degradation of tissue, ageing 
phenotypes or cancer [312]. It seems that malignant and benign SCs from 
the prostate maintain this protection mechanism and are therefore more 
resistant to DNA damage induced by chemotherapy or irradiation. The 
higher proportion of SCs (benign and malignant origin) in a quiescent stage 
was also confirmed by a series of experiments in our group that used Ki67 
staining and EdU incorporation (BrdU analogue) on a different set of primary 
samples (personal communication with F.M. Frame). The mainly quiescent 
nature of CD133+/α2β1integrinhigh SCs was also confirmed by [106]. The 
authors isolated SCs directly from BPH samples and assess Ki67 expression 
[106]. More than 80% of the SCs were found to be dormant [106]. Data from 
other groups support the hypothesis that dormancy occurs frequently in 
CSCs and concur with our results. For example CML-SCs were dormant and 
it was speculated that this is a likely resistance mechanism against anti-
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cancer treatment [313, 314]. Quiescence has also been reported for CSCs 
from the esophageal, rectal carcinoma, breast and pancreatic tumours [289, 
290, 315, 316]. 
A link between the slow cycling nature of CSC populations and therapy 
resistance has been demonstrated in the colon, breast, ovaries, and 
pancreas [247, 249, 251, 316]. Quiescent CSCs survived in vivo therapies 
that killed the bulk tumour cells and required in vitro increased doses to 
decrease viability in comparison to rapidly cycling cells [247, 249, 251, 
316]. These findings emphasis how ineffective conventional therapies can 
be on dormant cells and can provide explanations why tumors that seem to 
be entirely regressed after treatment can recur [242]. 
To kill quiescent CSCs successfully, the application of agents that target 
non-cycling cancer cells must be the alternative. It would have been 
interesting to assess a substance that acts in a cell cycle independent 
fashion such as the trk tyrosine kinase inhibitor CEP-751 (KT6587) that has 
been used to examine the elimination of prostate cancer in animal models 
[317]. Alternatively, dormant cells could be treated in a manner that 
encourages them to re-enter the cell cycle. Such an approach was made for 
hematopoietic SCs that were switched from dormancy to self-renewal 
following stimulation with G-CSF [298]. This mechanism might offer a novel 
treatment option and be meaningful for the eradication of malignancy. 
Indeed, CML-SCs were eliminated in vitro by imatinib when pre-treated with 
G-SCF [318]. However, one of the main challenges for the clinical use of 
these substances will be to activate specifically CSCs whilst sparing healthy 
SCs. Targeting healthy SCs would be dangerous for the patient and lead to 
tissue atrophy or indeed could drive malignancy. At this time there is no 
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substance available that switches exclusively CSCs from dormancy to an 
activated stage. Hence, further research into substances and their suitability 
for clinical use is required. 
4.4 Apoptotic inhibition in prostate primary cells  
The mechanism of action of our “model drug” etoposide is the induction of 
apoptosis by inhibiting topoisomerase II [277, 319, 320], even if some 
studies reported that, paradoxically, etoposide might also reduce the 
expression of several caspases and Bcl-2 related genes [321]. We found that 
malignant and benign primary prostate epithelial cells failed to undergo 
apoptosis following etoposide treatment, whereas the prostate cell lines 
RC92a/ h-TERT and RC165N/h-TERT were able to do so. This effect seems 
not only to be observed after etoposide treatment of prostate epithelial 
primary cells, but also after high doses of irradiation (personal 
communication with F.M. Frame). Recent reports which addressed the 
question of apoptotic resistance in prostate cells agree with our findings. A 
higher susceptibility of prostate cell lines to apoptosis in comparison to 
primary cells has been seen after treatment with drugs such as docetaxel, 
mitoxantrone, methotrexate  or cisplatin [267]. The immortalization of the 
cell lines obviously led to genetic changes that altered their response to 
treatment.  
Apoptotic resistance remains one of the main obstacles to successful cancer 
therapy. Its failure can depend on many molecular factors, for example p53, 
the members of the Bcl-2 family, NF-ƘB and beclin1. Bcl-2 overexpression 
has been linked to a failure of treatment strategies such as radiation, 
chemotherapeutic drugs (e.g. docetaxel) or androgen deprivation [308, 
322]. p53 is frequently mutated in metastatic prostate cancer [68, 323, 324] 
and its lack of  function has been shown to inhibit apoptosis in cell lines and 
                                                                                                   DISCUSSION 
 
167 
 
(primary) prostate cells preventing the success of anti-cancer treatment  
[307, 325]. The pro-apoptotic regulators Fau and Bcl-G were downregulated 
in prostate tumours relative to normal prostate tissue and BPH and shown to 
play a role in apoptotic sensitivity [309]. Also the repair factor γH2A.X, 
which we found to be up-regulated after etoposide treatment, is thought to 
play a role in treatment success by maintaining cell cycle arrest and 
preventing apoptosis [326], even though γH2A.X has also been described as 
a marker for the genotoxic endpoint of the cell [143].  
As we didn’t detect apoptosis in primary prostate epithelial cells, we took 
alternative cellular responses such as senescence, necrosis and autophagy 
into consideration. As primary prostate epithelial cells displayed enlarged 
vacuoles after etoposide treatment (experiment conducted for a different 
study by a former lab member), we decided to test for autophagy as an 
alternative treatment response. Preliminary findings demonstrated the 
presence of LC3B positive cells following the administration of etoposide. 
Indeed, autophagy is known as a resistance mechanism for multiple 
therapeutic substances in the setting of apoptotic inhibition [218-220]. In 
vivo and in vitro work on the prostate cancer cell lines PC-3 and LNCaP has 
demonstrated autophagy as a mechanism to escape apoptosis [219]. By 
inhibiting autophagy the authors observed an increased ability of the cells  
to trigger programmed cell death [219]. It is possible that our primary 
prostate epithelial cells used autophagy as a resistance mechanism.  
In conclusion, the observed apoptotic resistance can rely on many factors. 
To encourage an apoptotic mechanism in primary prostate epithelial cells, it 
would probably be necessary to block anti-apoptotic factors before the 
administration of therapy. As we found cells to be autophagy positive, it 
would have been interesting to pursue this work e.g. by down-regulating 
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the autophagy gene beclin1 prior to the treatment. To reveal more detailed 
information it would also be crucial to assess these impacts on selected 
populations. Based on previous reports it is likely that SCs are more 
resistant to apoptosis [109, 113, 327] e.g. through expression of NF-ĸB 
[109, 113]. The differential findings concerning the apoptotic sensitivity in 
cell lines vs. primary cells confirm the importance of the use of cells from 
primary tissues for research.  
4.5 The role of ABC-transporters in mediating therapy-resistance 
4.5.1 Gene expression analysis of ABC-transporters  
ABC multidrug transporters are expressed in many human tumours. They 
are a major cause of chemoresistance and have also been identified in 
prostate cell lines and primary prostate cells [266, 267, 299, 300]. Our gene 
expression analysis of ABC-transporters in SCs and CBs from malignant and 
benign primary prostate tissues indicated the presence of ABC-transporters 
in SCs and CBs, suggesting they might be a factor in therapy failure. Out of 
the 10 ABC-transporters present on the array ABCB1 (Pg-G), ABCC1 (MRP-
1), ABCG2 (MRP), ABCC3 and ABCC6 are known to transport etoposide [279, 
280]. In particular ABCB1, ABCC1 and ABCG2 belong to the three major 
types of ABC-transporters correlated with drug resistance and were 
therefore of further interest. The ABCB1 gene is expressed in many cancer 
cells including primary malignant and non-malignant prostate cells [266, 
302], whereas other studies revealed that it is not present at the protein 
level [303, 328]. In our gene expression analysis ABCB1 was found in about 
50% of the tested samples, even though its expression at mRNA level was 
very low in comparison to other ABC-transporters. ABCB1 is therefore 
unlikely to play a main role in drug resistance. Further etoposide-
transporting proteins such as ABCG2, ABCC1, ABCC3 and ABCC6 were 
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(highly) expressed in all of the samples tested. In particular the expression 
of ABCG2 and ABCC1 has been reported for primary prostate tissue and 
prostate cell lines and is in accordance with our results [266, 267, 299, 
300]. Interestingly, the etoposide-transporting ABCC1 is more highly 
expressed in malignant and benign SCs, whereas ABCB5 (which is not known 
to transport etoposide) is significantly highly expressed in CBs. These data 
suggest that malignant and benign SCs might be able to eliminate etoposide 
more efficiently, due to increased ABCC1 expression. However, some ABC-
transporters which are not known as etoposide transporting systems might 
still be able to efflux etoposide, even if not specifically described in the 
literature. Following this gene expression analysis we decided to pursue a 
functional assay for ABC-transporters. 
4.5.2 Calcein efflux assays to assess the functionality of ABC-
transporters in primary prostate tissue 
In order to reveal more information about a potential influence of ABC-
transporters on drug resistance we applied calcein efflux assays to selected 
populations of primary prostate cells. Among other advantages (as 
described in results) calcein was considered as a suitable substance as it is a 
substrate of ABCC1. The application of calcein efflux assays demonstrated 
that malignant and benign SCs and their corresponding TAs and CBs were 
all able to efflux calcein, but SCs did not display enhanced efflux 
capabilities. A similar trend was observed in a series of experiments carried 
out by one of our lab members (David Hudson) aimed to define the so-
called “side population” with Hoechst 33342 (transported by ABCG2 and 
ABCB1, but not by ABCC1) in primary malignant and benign prostate cells. 
This “side population” has been described by other groups as a rare ABCG2-
positive population within a total population of cells that has SC 
characteristics and the ability to efflux fluorescent substances such as dye 
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cycle violet or Hoechst 33342 more efficiently than non-SCs [299, 300, 
304]. However, in the previously described study with Hoechst 33342, our 
lab could not identify the “side population”. The calcein assays and the 
Hoechst 33342 experiments covered the three main ABC-transporters and 
no specific efflux capabilities were seen in SCs. Our results suggest that 
malignant and benign SCs do not harbor increased efflux properties that 
might be an advantage in therapy survival. Based on these findings, the 
primary cause for the higher in vitro resistance to etoposide observed in 
malignant and benign SCs compared to their differentiated counterparts 
probably resides with other factors. Our findings are in contradiction to 
Brown et al. that has defined a “side population” of ABCG2-expressing 
malignant and benign prostate cells derived from primary tissues [305]. 
Possible explanations for these conflicting data might be factors such as a 
different type of preparation or differential growth conditions.  
Even if ABC-transporters were a primary cause for therapy resistance, 
attempts to improve the therapeutic outcome by inhibiting ABC-transporters 
have mainly failed in clinical trials. For example, blocking one of the most 
commonly known drug resistance proteins ABCB1 revealed only 
disappointing results, due to a lack of confirmation of ABCB1 expression in 
the tumour tissue prior to the administration of the treatment, lack of 
evidence of ABCB1 inhibition in vivo and ABCB1 inhibitor toxicity [329]. In 
patients with prostate cancer, ABC-transporters have been shown to 
influence the clinical outcome e.g. genetic variations in ABCB1 influence the 
toxicity and success of docetaxel therapy [301]. However, inhibitors of ABC-
transporters are not in clinical use for the treatment of prostate cancer. 
Furthermore, even if blocking of ABC-transporters could be easily achieved 
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in the clinic, it would be likely that additional mechanisms of therapy-
resistance prevent successful treatment. 
4.5.3 Limitations of the calcein assay  
The performance of calcein assays came with some challenges, which were 
mainly a consequence of the small SC numbers available, which limited the 
possibilities of the experimental design. The best option would have been a 
reagent that was highly fluorescent, transported by the three major ABC-
transporters and did not rely on metabolism. All of the available substances 
on the market such as doxorubicin, daunorubicin, mixatrone, Hoechst 
33342 and newer ones such as eFluxx—ID Green and Gold lack at least one 
of these features [281]. Another general limitation of efflux assays 
(including calcein assays) needs to be taken into consideration: a substance 
might be effluxed faster than its measurement in the cytoplasm can be 
conducted. For example in the case of calcein assays, the non-fluorescent 
calcein-am could be exported before its metabolism into the fluorescent 
calcein. However, for our study the risk of this effect is considered to be 
small, since: 
 Calcein-am is a substrate of ABCB1, which was only present in about 
50% of our samples and furthermore only weakly expressed.  
 The other two main ABC-transporters ABCG2 and ABCC1 do not 
appear to efflux calcein-am. ABCC1 takes calcein as a substrate but 
here no differences were observed among the populations.  
The available kits for efflux studies are certainly suitable for different kinds 
of studies, such as those that test efflux before and after application of an 
inhibitor, but are not ideal when comparing efflux in different cell types, in 
particular when cell numbers are limited. 
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In addition to the previously described calcein assays, an interesting type of 
experiment would be the use of an inhibitor against an efflux pump e.g. 
agosterol A or raloxifine against ABCC1 (significantly elevated at mRNA level 
in malignant and benign SCs) and subsequent assessment of calcein levels. 
A higher amount of calcein in the cytoplasm of inhibitor-treated cells vs. 
non-inhibitor-treated cells would have confirmed efflux and allowed firmer 
conclusions about the efficiency of the efflux pump. An inhibitor of ABCB1 
e.g. verapamil would block a potential efflux of the non-fluorescent calcein-
am. This would have eliminated some previously described issues: when 
calcein-am is prevented from exiting the cell, an accumulation of 
fluorescent calcein should be visible after time. The extent of calcein 
accumulation would allow conclusions regarding the efficiency of the pump 
when comparing it to a non-inhibitor treated control. However, these 
studies can only be performed, if a sufficient SC yield is available, which is 
usually not the case. A further interesting experiment would have been the 
use of inhibitors in combination with a chemotherapeutic drug, and the 
subsequent assessment of DNA damage or clonogenic recovery. However, 
three facts lead to the consideration that malignant and benign SCs are not 
in advantage due to increase effux capabilities:  
 At mRNA level we only found similar expressions of ABC-transporters 
in benign and malignant SCs and CBs (only ABCC1 and ABCB5 were 
different)  
 The selected populations in our calcein assays did not show 
significant efflux capabilities 
  This finding was backed up by independently performed tests with 
Hoechst 33342  
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In view of the finding that functional assays referring to the three main ABC-
transporters showed negative results, it was decided to focus on other 
potential mechanisms of therapy resistance. 
4.6 Concluding remarks 
In summary, our findings suggest that SCs from malignant and benign 
prostate tissues are more resistant to treatment than the corresponding TAs 
and CBs originating from the same outgrowth. Indeed, chemotherapy is not 
successful for the treatment of advanced prostate cancer, and this 
resistance might be mediated by surviving CSCs that repopulate the tumour 
mass. One important factor in therapy resistance might be cellular 
quiescence, as we can confirm for the SCs isolated from malignant and 
benign prostate tissues. The role of healthy SCs is to repair and repopulate a 
tissue after wounding. Therapies that decrease tumour size can be thought 
of as initiating an injury, to which the CSCs responds by going back into a 
proliferative stage [33].  In malignant tissue, this response might result in an 
increase in the tumour initiating or metastasis establishing cell pool [33]. 
Recently, the FDA in the USA has warned about the use of chemotherapy for 
the treatment of prostate cancer with inhibitors of 5-alpha reductase, which 
are designed to targets AR+ luminal cells [33]. Studies suggest that these 
agents promote poorly differentiated tumours in patients who had a pre-
existing tumour [33]. This is the likely response after the elimination of 
differentiated luminal cells resulting in the promotion of basal-like tumour 
cells.  
Due to this potentially fatal role for CSCs in therapeutic outcome, it is crucial 
to elucidate their mechanisms of therapy survival further. In addition to 
quiescence as demonstrated in our study, there might be a wide range of 
other mechanisms. For instance, it would have been interesting to assess 
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the role of ROS detoxifying enzymes in SCs isolated from prostate tumours. 
It would have also been logical to assess the role of autophagy in apoptotic 
inhibition further. Upon the confirmation of SCs relevance in treatment 
resistance to conventional therapies a screen to identify agents that 
specifically target CSCs would have been an important step. The elucidation 
of these mechanisms and the identification of treatments to block them 
might be an important future direction for the elimination of prostate 
tumours. 
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Appendix 
Chapter III Results: Comet assays 
Figure 3-5: Alkaline Comet assays less than 50 events. Due to the availability of SCs 
a lower number of events (lower than 50) had to be analyzed for the alkaline comet 
assays (cancer and benign samples). 
SCs 45 min,  250 µM  
sample number of cells data point in graph 
H031/10  38 1.36 
Y025/09 11 1.6 
SCs 3 h,  30µM  
 sample number of cells data point in graph 
H018/09  23 3.09 
Y004/09 40 0.662 
H035/11  43 1.09 
 
Figure 3-5: p-values determined by Wilcoxon rank sum test for alkaline comet 
assays (cancer and benign samples). Significant p-values shown in bold. 
45 min, 30 µM 
SC vs. CB p=0.007 
SC vs. TA p= <0.001 
CB vs. TA p=0.257  
45 min, 250 µM 
SC vs. CB p= 0.686 
SC vs. TA p = 0.0029 
CB vs. TA p = 0.114 
3 h, 30 µM 
SC vs. CB  P = 0.222 
SC vs. TA p = 0.056 
CB vs. TA p = 0.421 
3 h, 250 µM 
SC vs. CB p = 0.667 
SC vs. TA p = 0.667 
CB vs. TA p = 0.667 
 
Figure 3-6 A: p-values determined by Wilcoxon rank sum test for alkaline comet 
assays (cancer samples). Significant p-values shown in bold. 
45 min, 30 µM 
SC vs. CB p= 0.095 
SC vs. TA p= 0.008 
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CB vs. TA P=0.0421 
 
Figure 3-6 B: p-values for alkaline comet assays determined by Wilcoxon rank sum 
test (benign samples). Significant p-values shown in bold. 
45 min, 30 µM 
SC vs. CB p= 0.056 
SC vs. TA p= 0.008 
CB vs. TA P=0.548 
 
Chapter III Results: γH2A.X assays 
Figure 3-11: p-values determined by Wilcoxon rank sum test for γH2A.X assays 
(cancer samples). Significant p-values shown in bold. 
45 min, 30 µM 
SC vs. TA p=0.032 
24 h, 30 µM 
SC vs. TA p=0.114 
 
Figure 3-12: p-values determined by Wilcoxon rank sum test for γH2A.X assays 
(benign samples). 
45 min, 30 µM 
SC vs. TA p=0.222 
24 h, 30 µM 
SC vs. TA p=0.310 
 
Figure 3-11 and Figure 3-12: p-values yH2A.X assays determined by paired t-test 
and Wilcoxon rank sum test to assess repair. Significant p-values are shown in bold. 
Paired t-test 
Cancer 
SC 45 min vs. SC 24 h P = 0.222 
TA 45 min vs. TA 24 h P = 0.117 
Benign 
SC 45 min vs. SC 24 h p=0.047 
TA 45 min vs. TA 24 h p=0.047 
Wilcoxon signed rank test 
Cancer 
SC 45 min vs. SC 24 h P = 0.250 
TA 45 min vs. TA 24 h P = 0.250 
Benign 
SC 45 min vs. SC 24 h P = 0.063 
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TA 45 min vs. TA 24 h P = 0.063 
 
Figure 3-13 A-D: p-values determined by Wilcoxon rank sum test for the 
quantification of different γH2A.X foci types (benign and malignant samples). 
Significant p-values are shown in bold. 
Quantification of different foci types 
Cancer 45 min, 30 µM SC vs. TA 
5-10 foci p = 0.841 
>10 p = 0.032 
PL p = 0.421 
PI p = 0.548 
PS p = 0.841 
Cancer 24 h, 30 µM SC vs. TA 
5-10 foci p = 1.000 
>10 p = 0.100 
PL p = 0.400 
PI p = 0.200 
PS p = 0.200 
Benign 45 min, 30 µM SC vs. TA 
5-10 foci p = 0.310 
>10 p = 0.421 
PL p = 1.000 
PI p = 0.421 
PS p = 0.222 
Benign 24 h, 30 µM SC vs. TA 
5-10 foci p = 0.421 
>10 p = 0.095 
PL p = 0.841 
PI p = 0.310 
PS p = 0.690 
 
Figure 3-13 A-D: Fold-changes for the quantification of different γH2A.X foci types 
(benign and cancer samples). The median values graphed in Figure 3-13 A-D are 
highlighted in pink. The fold changes were calculated by dividing the percentage of 
γH2A.X positive cells after treatment (45 min or 24 h time point) by the percentage 
before treatment. A 1-fold change was considered as no change, a fold change > 1 
was considered as an increase and a fold change <1 was considered as decrease. 
When 0 cells were positive for a distinct yH2A.X pattern 0 was replaced by 1 to 
calculate an approximate fold change.  
Cancer: SC; 45 min, 30 µM 
Sample H035/11  PE665 H054/11  H048/11 H049/11 
 5 to 10 
foci 0.85 to 7.69 0.81 to 3.2 0 to 2.56 0 to 0 2.83 to 0.85 
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fold 
change 9.047058824 3.950617284 2.56 1 0.300353357 
> 10 4.24 to 6.73 8.87 to 4 8.40 to 10.26 4.85 to 3.85 5.66 to 38.14 
fold 
change 1.587264151 0.450958286 1.221428571 0.793814433 6.734982332 
PL 16.10 to 8.65 3.23 to 21.6 3.36 to 7.69 2.91 to 7.69 0.94 to 1.69 
fold 
change 0.537267081 6.687306502 2.288690476 2.642611684 1.79787234 
PI 4.24 to 6.73 0.81 to 18.4 15.97 to 10.26 1.94 to 5.77 2.83 to 3.39 
fold 
change 1.587264151 22.71604938 0.642454602 2.974226804 1.197879859 
PS 1.69 to 1.92 1.61 to 1.6 0 to 3.85 0 to 0 0 to 12.71 
fold 
change 1.136094675 0.99378882 3.85 1 12.71 
 
 
Cancer: TA; 45 min, 30 µM 
Sample  H035/11  PE665 H054/11  H048/11 H049/11 
 5 to 10 
foci 2.1 to 4.38 0 to 17.61 1.35 to 5 0 to 1.47 0 to 0 
fold 
change 2.085714286 17.61 3.703703704 1.47 1 
> 10 5.6 to 29.2 4.20 to 26.06 6.08 to 45 0 to 9.56 3.5 to 54.14 
fold 
change 5.214285714 6.204761905 7.401315789 9.65 15.46285714 
PL 2.8 to 7.3 0 to 10.56 2.70 to 0.83 0 to 7.35 1.4 to 8.27 
fold 
change 2.607142857 10.56 0.307407407 7.35 5.907142857 
PI 1.4 to 16.79 0 to 12.68 4.73 to 15 0 to 2.21 0 to 0.75 
fold 
change 11.99285714 12.68 3.171247357 2.21 0.75 
PS 1.4 to 1.46 0 to 11.27 0 to 1.67 4.41 to 0 0.7 to 21.05 
fold 
change 1.042857143 11.27 1.67 0.22675737 30.07142857 
 
 
Cancer: SC; 24 h, 30 µM 
Sample H035/11  H054/11  H049/11 
 5 to 10 
foci 0.85 to 1.64 0 to 0.98 2.83 to 1.39 
fold 
change 1.929411765 0.98 0.491166078 
> 10 4.24 to 0.82 8.40 to 0 5.66 to 0.7 
fold 
change 0.193396226 0.119047619 0.123674912 
PL 16.10 to 11.48 3.36 to 5.88 0.94 to 10.42 
fold 
change 0.713043478 1.75 11.08510638 
PI 4.24 to 3.28 15.97 to 8.82 2.83 to 9.03 
fold 
change 0.773584906 0.552285535 1.197879859 
PS 1.69 to 1.64 0 to 0 0 to 0 
fold 0.970414201 1 1 
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change 
 
 
Cancer: TA; 24 h, 30 µM 
Sample H035/11  H054/11  H049/11 
 5 to 10 
foci 2.1 to 4.03 1.35 to 0 0 to 9.68 
fold 
change 1.919047619 0.740740741 1 
> 10 5.6 to 2.42 6.08 to 1.71 3.5 to 7.26 
fold 
change 0.432142857 0.28125 2.074285714 
PL 2.8 to 23.39 2.70 to 12.82 1.4 to 21.77 
fold 
change 8.353571429 4.748148148 15.55 
PI 1.4 to 12.9 4.73 to 5.13 0 to 13.71 
fold 
change 9.214285714 1.084566596 13.71 
PS 1.4 to 3.23 0 to 0 0.7 to 4.03 
fold 
change 2.307142857 1 5.757142857 
 
 
Benign: SC; 45 min, 30 µM 
Sample HO53/11  YO25/09  YO30/11 YO23/09  YO31/11 
 5 to 10 
foci 0 to 2.86 0.75 to 0.97 0 to 0 0.81 to 0.75 1.89 to 1.03 
fold 
change 2.86 1.293333333 1 0.925925926 0.825242718 
> 10 0.86 to 15.24 3.76 to 5.83 2.44 to 0 
4.03 to 
18.05 3.77 to 7.22 
fold 
change 17.72093023 1.550531915 0.409836066 4.478908189 1.915119363 
PL 5.17 to 9.52 
1.50 to 
18.45 0 to 7.84 
8.87 to 
14.29 
10.38 to 
15.46 
fold 
change 1.84139265 12.3 7.84 1.611048478 1.489402697 
PI 8.62 to 6.67 0 to 9.71 6.1 to 2.94 
4.03 to 
21.05 1.89 to 22.68 
fold 
change 0.773781903 9.71 0.481967213 5.223325062 12 
PS 0 to 0 1.5 to 0.97 0 to 0 0 to 0.75 0 to 1.03 
fold 
change 1 0.646666667 1 0.75 1.03 
 
 
Benign: SC; 24 h,30 µM 
Sample HO53/11  YO25/09  YO30/11 YO23/09  YO31/11 
 5 to 10 foci 0 to 5.45 0.75 to 0 0 to 0 0.81 to 2.24 1.89 to 5.97 
fold change 5.45 1.333333333 1 2.765432099 3.158730159 
> 10 0.86 to 0 3.76 to 0 2.44 to 0 4.03 to 0 3.77 to 0.75 
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fold change 1.162790698 0.265957447 0.409836066 0.248138958 0.198938992 
PL 5.17 to 14.55 1.50 to 9.64 0 to 2.4 
8.87 to 
11.94 
10.38 to 
12.69 
fold change 2.814313346 6.426666667 2.4 1.346110485 1.222543353 
PI 8.62 to 3.64 0 to 2.41 6.1 to 3.2 4.03 to 0.75 
1.89 to 
16.42 
fold change 0.422273782 2.41 0.524590164 0.186104218 8.687830688 
PS 0 to 0 1.5 to 0 0 to 0 0 to 0 0 to 0 
fold change 1 0.666666667 1 1 1 
 
    
Benign: TA; 45 min, 30 µM 
Sample HO53/11  YO25/09  YO30/11 YO23/09  YO31/11 
 5 to 10 foci 0.83 to 0 6.29 to 3.05 2.4 to 6.02 1.72 to 0.74 11.67 to 0 
fold change 1.204819277 0.484896661 2.508333333 0.430232558 0.085689803 
> 10 10 to 78.81 1.4 to 9.92 1.2 to 8.27 
2.87 to 
20.74 5 to 7.53 
fold change 7.881 7.085714286 6.891666667 7.226480836 1.506 
PL 0.83 to 0 2.8 to 12.98 1.8 to 8.27 
5.17 to 
11.85 5.83 to 15.07 
fold change 1.204819277 4.635714286 4.594444444 2.292069632 2.58490566 
PI 0.83 to 4.24 2.1 to 31.3 2.4 to 12.78 8.62 to 29.3 0.83 to 27.4 
fold change 5.108433735 14.9047619 5.325 3.399071926 33.01204819 
PS 0 to 2.54 0 to 4.58 0.6 to 0 0 to 0 0 to 0.68 
fold change 2.54 4.58 1.666666667 1 0.68 
 
 
Benign: TA; 24 h, 30 µM 
Sample HO53/11  YO25/09  YO30/11 YO23/09  YO31/11 
 5 to 10 foci 0.83 to 8 6.29 to 4.51 2.4 to 0 1.72 to 5.13 11.67 to 3.85 
fold change 9.638554217 0.723370429 0.416666667 2.98255814 0.329905741 
> 10 10 to 3.2 1.4 to 13.53 1.2 to 0 
2.87 to 
17.09 5 to 3.08 
fold change 0.32 9.664285714 0.833333333 5.954703833 0.616 
PL 0.83 to 5.6 2.8 to 6.02 1.8 to 10.07 5.17 to 2.56 5.83 to 16.15 
fold change 6.746987952 2.15 5.594444444 0.49516441 2.770154374 
PI 0.83 to 0.8 2.1 to 9.77 2.4 to 4.32 
8.62 to 
14.53 0.83 to 13.08 
fold change 0.963855422 4.652380952 1.8 1.685614849 15.75903614 
PS 0 to 0 0 to 0 0.6 to 2.16 0 to 0.85 0 to 0 
fold change 1 1 3.6 0.85 1 
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Chapter III Results: Clonogenic assays 
Figure 3-16 A-C: Detailed information about the colony sizes including STDVs 
unselected Etoposide 45 min , 30 µM DMSO   
Y030/11    STDV    STDV 
 all 0.83 0.29 all 30.17 1.44 
 2+ 0 0 2+ 1 1 
 4+ 0 0 4+ 2,67 0.29 
 8+ 0.5 0.5 8+ 10.5 1.32 
 16+ 0.33 0.58 16+ 9.83 2.02 
 32+ 0 0 32+ 6.17 1.26 
 Etoposide 45 min, 250 µM DMSO  
    STDV   unselected STDV 
 all 0 0 all 33.17 17.56 
 2+ 0 0 2+ 0.33 0.29 
 4+ 0 0 4+ 4.67 2.84 
 8+ 0 0 8+ 9.33 7.59 
 16+ 0 0 16+ 11.17 2.89 
 32+ 0 0 32+ 7.67 4.51 
 Etoposide 3 h, 30 µM DMSO  
    STDV   unselected STDV 
 all 0 0 all 29.5 8.53 
 2+ 0 0 2+ 0.83 1.04 
 4+ 0 0 4+ 5.17 1.15 
 8+ 0 0 8+ 8.5 0 
 16+ 0 0 16+ 9.33 3.82 
 32+ 0 0 32+ 5.67 2.75 
 Etoposide  3 h, 250 µM DMSO  
   unselected STDV   unselected STDV 
 all 0 0 all 33.5 5.41 
 2+ 0 0 2+ 0.5 0.5 
 4+ 0 0 4+ 5.33 1.15 
 8+ 0 0 8+ 8.33 2.03 
 16+ 0 0 16+ 11 3.5 
 32+ 0 0 32+ 8.33 3.79 
       
 
Sample 
 
Day 3, DMSO 
PE531 Colony size TA SC TA STDV SC STDV 
 all 13.25 9.51 11.5 4.6 
 2+ 3.89 3.03 3.53 3.88 
 4+ 6.98 5.91 6.9 2.2 
 8+ 2.38 0.56 4.12 0.98 
 16+ 0 0 0 0 
 32+ 0 0 0 0 
 Day 3,  Etoposide 45 min, 30 µM 
 Colony size TA SC TA STDV SC STDV 
 all 0.61 0 1.05 0 
 2+ 0 0 0 0 
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 4+ 0.61 0 1.05 0 
 8+ 0 0 0 0 
 16+ 0 0 0 0 
 32+ 0 0 0 0 
 Day 6, DMSO 
 Colony size TA SC TA STDV SC STDV 
 all 46.61 46.17 7.94 19.53 
 2+ 0 1.7 0 1.87 
 4+ 1.13 2.73 1.96 1.01 
 8+ 12.41 10.74 5.09 4.73 
 16+ 15.34 11.98 7.37 6.48 
 32+ 16.72 19.02 2.22 6.72 
 Day 6, Etoposide 45 min, 30 µM 
 Colony size TA SC TA STDV SC STDV 
 all 4.34 12.21 4.73 3.92 
 2+ 0.52 0 0.9 0 
 4+ 0 0.93 0 1.6 
 8+ 0 4.26 0 1.1 
 16+ 3.82 4.87 3.91 1.01 
 32+ 0 2.14 0 0.55 
 
Sample Day 4, DMSO 
H035/11  Colony size TA SC TA STDV SC STDV 
 all 0.67 15.38 0.58 10.5 
 2+ 0 0.38 0 0.66 
 4+ 0 4.23 0 4.26 
 8+ 0.33 8.47 0.58 7.46 
 16+ 0 1.91 0 2.4 
 32+ 0.33 0.38 0.58 0.66 
 Day 4, Etoposide 45 min, 30 µM 
 Colony size TA SC TA STDV SC STDV 
 all 0 0.45 1.05 0 
 2+ 0 0 0 0 
 4+ 0 0 0 0 
 8+ 0 0 0 0 
 16+ 0 0 0 0 
 32+ 0 0.45 0 0.78 
 Day 8,  DMSO 
 Colony size TA SC TA STDV SC STDV 
 all 7.67 14.73 5.03 3.03 
 2+ 0 0 0 0 
 4+ 0.33 0 0.58 0 
 8+ 0 0 0 0 
 16+ 2.33 2.79 2.52 2.52 
 32+ 5 11.94 2 1.65 
 Day 8, Etoposide 45 min, 30 µM 
   TA SC TA STDV SC STDV 
 all 1.67 5.47 1.15 0.95 
 2+ 0 0.45 0 0.78 
 4+ 0 0.36 0 0.62 
 8+ 0.33 0.36 0.58 0.62 
 16+ 0.33 1.52 0.58 2.62 
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 32+ 1 2.79 1 2.42 
 
Figure 3-17 A-C: Detailed information about the colony sizes including STDVs and 
p-values 
Sample Colony size 
%TA colonies  
normalized 
to vehicle 
control 
%SC colonies 
normalized 
to vehicle 
control TA STDV SC STDV 
H035/11   all 21.74 37.13 15.06 6.48 
  2+ 0 3.06 0 5.3 
  4+ 0 2.43 0 4.22 
  8+ 4.35 2.43 7.53 4.22 
  16+ 4.35 10.29 7.53 17.82 
  32+ 13.04 18.91 13.04 16.4 
PE531 all 9.51 26.45 10.36 8.5 
  2+ 1.14 0 1.98 0 
  4+ 0 2 0 3.47 
  8+ 0 9.26 0 2.4 
  16+ 8.37 10.55 8.57 2.2 
  32+ 0 4.63 0 1.2 
H087/11 all 10.44 17.16 5.5 11.71 
  2+ 0 2.52 0 4.36 
  4+ 2.99 7.33 2.63 7.56 
  8+ 3.46 2.52 6 4.36 
  16+ 2.66 0 4.61 0 
  32+ 1.33 4.8 2.31 4.17 
H049/11 all 23.22 22.44 7.04 13.58 
  2+ 0 2.23 0 1.97 
  4+ 4.44 4.5 3.88 4 
  8+ 1.58 5.74 2.74 5.62 
  16+ 9.68 0.98 0.49 1.7 
  32+ 7.51 8.98 1.76 13.09 
H048/11  all 6.45 11.55 4.39 6.4 
  2+ 0 0.76 0 1.32 
  4+ 0.23 2.41 0.41 0.32 
  8+ 3.06 3.81 2.67 4.43 
  16+ 1.68 2.28 1.54 3.96 
  32+ 1.46 2.28 1.27 3.96 
H054/11  all 8.61 25.38 2.65 3.1 
  2+ 0 0 0 0 
  4+ 1.09 2.7 0.61 2.36 
  8+ 1.63 10.22 0.18 8.98 
  16+ 3.2 8.07 2.4 5.1 
  32+ 2.68 4.4 0.85 1.92 
Y062/11 all 33.36 78.81 12.03 75.65 
  2+ 0 0 0 0 
  4+ 0 0 0 0 
  8+ 14.1 53.67 15.5 46.76 
  16+ 3.82 0 6.61 0 
  32+ 15.44 25.14 17.78 43.55 
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Y031/11  all 21.66 1.69 27.45 1.53 
  2+ 0 0 0 0 
  4+ 2.74 0 4.74 0 
  8+ 4.63 0.69 4.3 1.19 
  16+ 10.13 0.5 14.92 0.86 
  32+ 4.17 0.5 3.52 0.86 
Y030/11 all 6.82 12.94 1.13 3.03 
  2+ 0 0 0 0 
  4+ 0 0 0 0 
  8+ 1.24 5.92 0.91 1.36 
  16+ 2.79 4.93 1.59 1.97 
  32+ 2.79 2.09 0.86 2.59 
 
Figure 3-17 A and B: p -values for the clonogenic assays 
Sample SC vs. TA 
H035/11   p = 0.400 
PE531  p = 0.100 
H048/11 p = 0.400 
H087/11  p= 0.700 
H049/11 p = 1.000 
H054/11 p = 0.100 
Y062/11 p= 0.700 
Y031/11  p = 0.100 
Y030/11  p = 0.100 
 
Etoposide  3 h, 30 µM 
Colony size TA SC TA STDV SC STDV 
all 0 7.07 0 12.25 
2+ 0 0 0 0 
4+ 0 0 0 0 
8+ 0 4.72 0 8.17 
16+ 0 0 0 0 
32+ 0 2.36 0 0 
 
Chapter III Results: KI67 
Figure 3-19 A-B:  p-values for Ki67 assessment. Significant p-values are shown in 
bold. 
Malignant   
TA vs. SC  P = 0.016  
CB vs. SC  P = 0.008  
CB vs. TA  p = 0.310  
Benign   
TA vs. SC    P=0.065 
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CB vs. SC  P=0.065 
CB vs. TA   p=0.31 
 
 
Chapter III Results: MTS assay 
 
Figure 3-20: Concentrations for MTS assay 
 
Chapter III: Calcein efflux assays 
Figure 3-27 D: STDVs for calcein efflux 
STDVs of the triplicates measured  for H054/11  
   15 min 1 h 2 h 3 h 
CB 1131.8491 2483.0989 1826.0665 949.28763 
TA 5763.4303 4613.0499 4088.4203 4281.2879 
 
Figure 3-31: STDVs for calcein efflux and p-values 
H054/11 STDV 
TA 26.683004 
CB 7.6389123 
H092/11 STDV 
TA 11.352347 
CB 21.206506 
H035/11 STDV 
TA 12.294343 
CB 18.578056 
Y030/11 STDV 
TA 12.268419 
CB 4.9243582 
Y075/11 STDV 
Concentration→ 
Replication inhibitor↓ 
      
Camptothecin 32µM 12.8µM 5.1µM 2µM 0.8µM 0.32µM 
Carboplatin 64µM 25.6µM 10.2µM 4.1µM 1.6µM 0.6µM 
Docetaxel 12.8µM 5.12µM 2µM 0.8µM 0.32µM 0.128µM 
Doxorubicin 12.8µM 5.12µM 2µM 0.8µM 0.32µM 0.128µM 
Etoposide 64µM 25.6µM 10.2µM 4.1µM 1.6µM 0.6µM 
DMSO (carrier) 1:1562 1:3906 1:9762 1:24406 1:61015 1:152539 
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TA 14.040624 
CB 11.879222 
 
SC vs. TA SC vs. CB TA vs. CB 
P = 0.690 P = 0.690 P = 1.000 
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